Indole and azaindole inhibitors of PAD enzymes

Abstract

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods for treating PAD4-associated disorders.

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 62 / 715,850, filed August 8, 2018, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] PAD4 is a member of the peptidylarginine deiminase (PAD) family of enzymes that has the ability to catalyze the citrullination of arginine to citrulline within peptide sequences. PAD4 is involved in the deimination or citrullination of various proteins in vitro and in vivo, resulting in pleiotropic functional responses in various diseases (Jones JE et al., Curr. Opin. Drug Discov. Devel., 12(5)(2009),616-627). Typical disease examples include rheumatoid arthritis, diseases with neutrophil contribution to pathogenesis (e.g., vasculitis, systemic lupus erythematosus, ulcerative colitis), in addition to oncology indications. PAD4 inhibitors also have broad applicability as tools and therapeutics for human diseases through epigenetic mechanisms.

[0003] Inhibitors of PAD4 are useful for rheumatoid arthritis (RA). RA is an autoimmune disease that affects about 1% of the population (Wegner N. et al., Immunol. Rev., 233(1)(2010), 34-54). RA is characterized by joint inflammation that leads to debilitating destruction of bone and cartilage. Although not consistent, many population studies have suggested a weak genetic association between PAD4 polymorphisms and susceptibility to RA (Kochi Y. et al., Ann. Rheum. Dis., 70(2011),512-515). PAD4 (along with family member PAD2) has been detected in synovial tissue, where it is involved in the deimination of various joint proteins. It is speculated that this process leads to the breakdown of tolerance to citrullinated substrates, such as fibrinogen, vimentin and collagen, and the initiation of an immune response against said substrates in RA joints. These anti-citrullinated protein antibodies (ACPAs) contribute to disease pathogenesis and may be used as diagnostic tests for RA (e.g., commercially available CCP2 or cyclic citrullinated protein 2 tests). In addition, increased citrullination may also confer an additional direct contribution to disease pathogenesis through its ability to directly affect the function of several joint and inflammatory mediators (e.g., fibrinogen, antithrombin, multiple chemokines). Anti-PAD4 antibodies can be measured in a subpopulation of RA patients and may correlate with more aggressive forms of the disease.

[0004] PAD4 inhibitors are also useful in reducing pathological neutrophil activity in a variety of diseases. Studies have shown that the process of neutrophil extracellular trap (NET) formation, an innate defense mechanism by which neutrophils can immobilize and kill pathogens, is associated with histone citrullination and is defective in PAD4 knockout mice (Neeli I. et al., J. Immunol., 180(2008), 1895-1902, and Li P. et al., J. Exp. Med., 207(9)(2010), 1853-1862). Thus, PAD4 inhibitors may be applicable to diseases in which NET formation in tissues contributes to local damage and disease pathology. Such diseases include small vessel vasculitis (Kessenbrock K. et al., Nat. Med., 15(6)(2009), 623-625), systemic lupus erythematosus (Hakkim A. et al., Proc. Natl. Acad. Sci. USA, 107(21)(2010), 9813-9818, and Villanueva E. et al., J. Immunol., 187(1)(2011), 538-52), ulcerative colitis (Savchenko A. et al., Pathol. Int., 61(5)(2011), 290-7), cystic fibrosis, asthma (Dworski R. et al., J. Allergy Clin. Immunol., 127(5)(2011), 1260-6), deep vein thrombosis (Fuchs T. et al., Proc. Natl. Acad. Sci. USA, 107(36)(2010), 15880-5), periodontitis (Vitkov L. et al., Ultrastructural Pathol., 34(1)(2010), 25-30), sepsis (Clark SR et al., Nat. Med., 13(4)(2007), 463-9), appendicitis (Brinkmann V. et al., Science, 303(2004), 1532-5), and stroke.In addition, there is evidence that NETs may contribute to pathology in diseases affecting the skin, such as cutaneous lupus erythematosus (Villanueva E. et al., J. Immunol., 187(1)(2011), 538-52) and psoriasis (Lin AM et al., J. Immunol., 187(1)(2011), 490-500), and therefore PAD4 inhibitors, when administered systemically or via cutaneous routes, may be beneficial in addressing NET skin diseases. PAD4 inhibitors affect additional functions within neutrophils and may have broader applicability to neutrophil diseases.

[0005] Studies have demonstrated the efficacy of PAD inhibitors (e.g., chloroamidines) as tools in a number of animal models of disease, including collagen-induced arthritis (Willis VC et al., J. Immunol., 186(7)(2011), 4396-4404), dextran sulfate sodium (DSS)-induced experimental colitis (Chumanevich AA et al., Am. J. Physiol. Gastrointest. Liver Physiol., 300(6)(2011), G929-G938), spinal cord repair (Lange S. et al., Dev. Biol., 355(2)(2011), 205-14), and experimental autoimmune encephalomyelitis (EAE). The DSS colitis report also demonstrated that chloroamidines promote apoptosis of inflammatory cells both in vitro and in vivo, suggesting that PAD4 inhibitors may be more generally effective in a wide range of inflammatory diseases.

[0006] PAD4 inhibitors are also useful in the treatment of cancer (Slack JL et al., Cell. Mol. Life Sci., 68(4)(2011), 709-720). Overexpression of PAD4 has been demonstrated in many cancers (Chang X. et al., BMC Cancer, 9(2009), 40). An antiproliferative role for PAD4 inhibitors is suggested by the observation that PAD4 citrullinates arginine residues in histones in the promoters of p53 target genes, such as p21, involved in cell cycle arrest and induction of apoptosis (Li P. et al., Mol. Cell Biol., 28(15)(2008), 4745-4758).

[0007] The above-mentioned role of PAD4 in deiminating arginine residues in histones may indicate a role for PAD4 in epigenetic regulation of gene expression. PAD4 is the major PAD family member found endogenously in the nucleus as well as in the cytoplasm. Early evidence that PAD4 may act as a histone demethyliminase is inconsistent and unproven. However, it may indirectly reduce histone arginine methylation (and thus epigenetic regulation associated with this mark) through depletion of available arginine residues by conversion to citrulline. PAD4 inhibitors are useful as epigenetic tools or therapeutic agents to affect the expression of various target genes in additional disease settings. Through such a mechanism, PAD4 inhibitors may also be effective in controlling citrullination levels in stem cells, and thus may therapeutically affect the pluripotent state and differentiation potential of a wide variety of stem cells, including but not limited to embryonic stem cells, neural stem cells, hematopoietic stem cells and cancer stem cells. Thus, there remains an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated disorders. Summary of the Invention

[0008] This time, the formula (I): [ka] wherein each ring A, L, Q, R1, R2, R3, R4, R7, and R8, together with other variables, are as defined herein. It has been found that compounds of the formula: are useful as inhibitors of PAD4.

[0009] In some embodiments, provided compounds show selectivity for PAD4 over PAD2.The present invention also provides pharma- ceutically acceptable compositions comprising provided compounds.Provided compounds are useful in treating various disorders associated with PAD4.Such disorders are described in detail herein, and include, for example, rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] 1. General Description of Certain Aspects of the Invention In some embodiments, such compounds include compounds represented by the formulas described herein, or pharma- ceutically acceptable salts thereof, wherein each variable is as defined herein or as described in the embodiments. Such compounds have the structural formula (I): [ka] [In formula: Q is selected from N and CH; Ring A is a 4- to 15-membered heterocyclyl substituted with 1 to 4 R7; R1 is selected from CH3 and CD3; R2 is H and 0-4 F, Cl and C 1-3 0-2 C substituted with alkyl 3-6 cycloalkyl; R3 is H, F, Cl, Br, -OR b , and 0 to 5 R e C replaced by 1-3 selected from alkyl; L is absent or -NR d -, -O-, -C(=O)NR d - and -S(O) p -More selected; R4 is 1 to 4 of F, OH, and C. 3-6 Cycloalkyl-substituted C 1-6 Alkyl, -(CH2) r -aryl substituted with 1 to 7 R5, -(CH2) r -C substituted with 1 to 7 R5 3-12 Cycloalkyl, -(CH2) r - selected from heterocyclyl containing a carbon atom and 1-3 heteroatoms selected from N, NR6, O, and S, and substituted with 1-7 R5; R5 is H, F, Cl, Br, CN, =O, nitro, 0 to 5 R e C replaced by 1-4 Alkyl, 0 to 5 R e C replaced by 2-4 Alkenyl, 0 to 5 R e C replaced by 2-4 Alkynyl, -(CHR d ) r OR b , -(CHR d ) r S(O) p R c , -(CHR d ) r S(O) p NR a R a , -(CHR d ) r NR a S(O) p R c , -(CHR d ) r NR a R a , -(CHR d ) r NR a C(=O)R b , -(CHR d ) r NR a C(=O)OR b , -(CHRd ) r NR a C(=O)NR a R a , -(CHR d ) r C(=O)R b , -(CHR d ) r C(=O)OR b , -(CHR d ) r C(=O)NR a R a , -(CHR d ) r OC(=O)R b , -(CHR d ) r OC(=O)OR b , -(CHR d ) r O(CH2) r C(=O)NR a R a , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -(CH2) r C(=O)R b , -(CH2) r -C(=O)OR b , -(CH2) r C(=O)(CH2) r NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -S(O) p NR a R a , -(CH2) r -0 to 4 R e C replaced by 3-6 Cycloalkyl, -(CH2)r -0 to 4 R e Aryl substituted with -(CH2) r -0 to 4 R e heterocyclyl substituted with; R7 is H, F, Cl, CN, C 1-3 Alkyl, =N-OR b , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=NH)C 1-3 Alkyl, -NR a C(=O)OR b , carbocyclyl, and heterocyclyl; alternatively, two R7 groups taken together form a carbocyclyl or heterocyclyl; R8 is H, F, Cl, Br, or 0 to 5 R e C replaced by 1-4 independently selected from alkyl; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are H and 0 to 5 R e C replaced by 1-6 alkyl, and OH; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -aryl, -(CH2) r -heterocyclyl, Si(C 1-4 Alkyl)3, F, Cl, Br, CN, NO2, =O, CO2H, -(CH2) r OR f , S(O) p R f , C(=O)NR f R f , S(O) p NR f R f , and -(CH2)r NR f R f more independently selected; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 3-6 cycloalkyl, and phenyl; or R f and R f Together with the nitrogen atom to which they are both attached, 1-4 forming a heterocyclic ring which may be optionally substituted with alkyl; each p is independently selected from 0, 1, and 2; Each r is independently selected from 0, 1, 2, 3, and 4; however: (1) If L is absent, R4 is [ka] is a group other than (2) L is -NR d -, then R4 is [ka] is a group other than (3) When L is -O-, R4 is C 3-6 is a group other than cycloalkyl. or a pharma- ceutically acceptable salt thereof.

[0011] 2. Definition Throughout this specification and the appended claims, a given chemical formula or name encompasses all stereoisomers and optical isomers, as well as their racemates, when isomers exist. Unless otherwise specified, all chiral (enantiomers and diastereomers) and racemic forms are within the scope of the present invention. Many geometric isomers, such as C=C double bonds, C=N double bonds, ring systems, etc., can also exist in the compounds, and all such stable isomers are included in the present invention. Cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. The compounds of the present invention may be isolated in optically active or racemic forms. Optically active forms may be prepared by resolving racemic forms or by synthesis from optically active starting materials. All processes used to prepare the compounds of the present invention and intermediates prepared therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional means, for example, chromatography or fractional crystallization. Depending on the conditions of the process, the end products of the invention are obtained either in free (neutral) or salt form. Both the free and salt forms of these end products are within the scope of the invention. If desired, one form of the compound may be converted into another form. Free bases or acids may be converted into salts; salts may be converted into free compounds or into another salt; mixtures of isomeric compounds of the invention may be separated into individual isomers. The compounds of the invention, both in free form and salts, may exist in multiple tautomeric forms in which hydrogen atoms are transferred to other parts of the molecule and the chemical bonds between the atoms of the molecule are rearranged accordingly. It should be understood that all tautomeric forms, insofar as they exist, are included in the present invention.

[0012] As used herein, the term "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "C1-C 12 Alkyl" or "C 1-12"Alkyl" (or alkylene) is C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 and C 12 Including alkyl groups; C4-C 18 Alkyl" or "C 4-18 "Alkyl" (or alkylene) is a group consisting of C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 and C 18 Also, for example, "C1-C6 alkyl" or "C 1-6 "Alkyl" means an alkyl group having 1 to 6 carbon atoms. An alkyl group can be unsubstituted or substituted such that at least one hydrogen is replaced with another chemical group. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl). When "C0 alkyl" or "C0 alkylene" is used, it is intended to mean a direct bond.

[0013] "Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched configuration having the specified number of carbon atoms and one or more, preferably one or two, carbon-carbon double bonds which may be present in any stable position along the chain. For example, "C2-C6 alkenyl" or "C 2-6"Alkenyl" (or alkenylene) is intended to include C2, C3, C4, C5, and C6 alkenyl groups. Examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, and 4-methyl-3-pentenyl.

[0014] "Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration having one or more, preferably one to three, carbon-carbon triple bonds which may be present in any stable position along the chain. For example, "C2-C6 alkynyl" or "C 2-6 "Alkynyl" (or alkynylene) is intended to include C2, C3, C4, C5 and C6 alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl and hexynyl.

[0015] The term "alkoxy" or "alkyloxy" refers to an -O-alkyl group. For example, "C1-C6 alkoxy" or "C 1-6 "Alkoxy" (or alkyloxy) is intended to include C1, C2, C3, C4, C5, and C6 alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and t-butoxy. Similarly, "alkylthio" or "thioalkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulfur bridge, e.g., methyl-S- and ethyl-S-.

[0016] The term "halo" or "halogen" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and substituted with one or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl also include "fluoroalkyl", which is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and substituted with one or more fluorine atoms.

[0017] The term "cycloalkyl" refers to cyclic alkyl groups, including mono-, bi-, or poly-cyclic ring systems. For example, "C3-C6 cycloalkyl" or "C 3-6 "Cycloalkyl" is intended to include C3, C4, C5, and C6 cycloalkyl groups. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl". The term "cycloalkenyl" refers to a cyclic alkenyl group. 4-6 Cycloalkenyl is intended to include C4, C5, and C6 cycloalkenyl groups. Examples of cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, and cyclohexenyl.

[0018] As used herein, "carbocycle", "carbocyclyl" or "carbocyclic residue" is intended to mean any stable 3-, 4-, 5-, 6-, 7- or 8-membered mono- or bicyclic, or 7-, 8-, 9-, 10-, 11-, 12- or 13-membered bicyclic or tricyclic hydrocarbon ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic. Examples of such "carbocycles" include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As noted above, bridged rings are also included in the definition of carbocycle (e.g., [2.2.2]bicyclooctane). Preferred carbocycles, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, indanyl, and tetrahydronaphthyl. When the term "carbocycle" is used, it is intended to include "aryl". A bridged ring occurs when one or more, preferably 1 to 3, carbon atoms link two non-adjacent carbon atoms. Preferred bridges are 1 or 2 carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents on the ring may also be present on the bridge.

[0019] As used herein, the term "bicyclic carbocycle" or "bicyclic carbocyclic group" is intended to mean a stable 9- or 10-membered carbocyclic ring system containing two fused rings and made up of carbon atoms. One of the two fused rings is a benzo ring fused to a second ring; the second ring is a saturated, partially unsaturated, or unsaturated 5- or 6-membered carbocyclic ring. A bicyclic carbocyclic group may be attached to its pendant group at any carbon atom resulting in a stable structure. The bicyclic carbocyclic groups described herein may be substituted on any carbon, provided that the resulting compound is stable. Examples of bicyclic carbocyclic groups include, but are not limited to, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.

[0020] An "aryl" group refers to a monocyclic or bicyclic aromatic hydrocarbon, including, for example, phenyl and naphthyl. Aryl moieties are well known and are described, for example, in Lewis, RJ, ed., Hawley's Condensed Chemical Dictionary, 15th Edition, John Wiley & Sons, Inc., New York (2007). 6-10 "Aryl" refers to phenyl and naphthyl.

[0021] As used herein, the terms "heterocycle", "heterocyclyl" or "heterocyclic group" are intended to mean a stable 3-, 4-, 5-, 6- or 7-membered monocyclic or bicyclic, or 7-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered polycyclic heterocyclic ring that is saturated, partially unsaturated or fully unsaturated and contains carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; including any polycyclic group in which any of the above heterocyclic rings are fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N→O and S(O)). pwhere p is 0, 1 or 2). The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or other substituents, as defined). A heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on a carbon atom or on a nitrogen atom if the resulting compound is stable. A nitrogen of a heterocycle may optionally be quaternized. When the total number of S and O atoms in a heterocycle exceeds 1, it is preferred that these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in a heterocycle is 1 or less. When the term "heterocycle" is used, it is intended to include heteroaryl.

[0022] Examples of heterocycles include, but are not limited to, acridinyl, azetidinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahy- furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl , 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl, oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, phteridinyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolinyl pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,Examples of heterocyclic rings include 4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Fused ring and spiro compounds containing, for example, the above heterocycles are also included.

[0023] Examples of 5- to 10-membered heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1H-indazolyl, benzofuranyl, benzothiofuranyl, and benzothiofuranyl. nyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxyindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl.Fused ring and spiro compounds containing, for example, the above heterocycles are also included.

[0024] Bridged rings are also included in the definition of heterocycle. A bridged ring occurs when one or more, preferably one to three atoms (i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms. Examples of bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents depicted on the ring may also be present on the bridge.

[0025] As used herein, the term "bicyclic heterocycle" or "bicyclic heterocyclic group" is intended to mean a stable 9- or 10-membered heterocyclic ring system containing two fused rings and composed of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S. Of the two fused rings, one ring is a 5- or 6-membered monocyclic aromatic ring, including a 5-membered heteroaryl ring, a 6-membered heteroaryl ring, or a benzo ring, each of which is fused to a second ring. The second ring is a 5- or 6-membered monocyclic ring that is saturated, partially unsaturated, or unsaturated and includes a 5-membered heterocycle, a 6-membered heterocycle, or a carbocycle (provided that when the second ring is a carbocycle, the first ring is a ring other than benzo).

[0026] A bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The bicyclic heterocyclic groups described herein may be substituted at carbon or nitrogen atoms if the resulting compound is stable. If the total number of S and O atoms in the heterocyclic ring exceeds 1, then it is preferred that these heteroatoms are not adjacent to each other. It is preferred that the total number of S and O atoms in the heterocyclic ring does not exceed 1.

[0027] Examples of bicyclic heterocyclic groups include, but are not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, 1H-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 2,3-dihydrobenzofuranyl, chromanyl, 1,2,3,4-tetrahydroquinoxalinyl, and 1,2,3,4-tetrahydroquinazolinyl.

[0028] As used herein, the term "aromatic heterocyclic group" or "heteroaryl" refers to stable monocyclic and polycyclic aromatic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl, and benzodioxane. Heteroaryl groups may be substituted or unsubstituted. The nitrogen atoms are substituted or unsubstituted (i.e., as defined, N or NR, where R is H or other substituents). The nitrogen and sulfur heteroatoms are optionally oxidized (i.e., N→O and S(O)). p where p is 0, 1 or 2).

[0029] Examples of 5-6 membered heteroaryls include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, imidazolyl, imidazolidinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.

[0030] The term "counterion" refers to a negatively charged species, such as chloride, bromide, hydroxide, acetate, and sulfate, or sodium (Na + ), potassium (K + ), Ammonium (R n NH m + (n=0-4, m=0-4), etc.

[0031] When a dotted ring is used within a ring system, this indicates that the ring system may be saturated, partially saturated or unsaturated.

[0032] As used herein, the term "amine protecting group" refers to any group known in the art of organic synthesis for protecting amine groups that is stable to ester reducing agents, disubstituted hydrazines, R4-M and R7-M, nucleophiles, hydrazine reducing agents, activators, strong bases, hindered amine bases, and cyclizing agents. Such amine protecting groups that meet these criteria include those listed in Wuts, PGM et al., Protecting Groups in Organic Synthesis, 4th Edition, Wiley (2007) and The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981), the contents of which are incorporated herein by reference. Examples of amine protecting groups include, but are not limited to, the following: (1) acyl type, such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; (2) aromatic carbamate type, such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); (3) aliphatic carbamate type, such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; (4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; (5) alkyl types such as triphenylmethyl and benzyl; (6) trialkylsilanes such as trimethylsilane; (7) thiol-containing types such as phenylthiocarbonyl and dithiasuccinoyl; and (8) alkyl types such as triphenylmethyl, methyl, and benzyl; and substituted alkyl types such as 2,2,2-trichloroethyl, 2-phenylethyl, and t-butyl; and trialkylsilane types such as trimethylsilane.

[0033] The term "substituted" as referred to herein means that at least one hydrogen atom is replaced with a group other than hydrogen, provided that normal valences are maintained and the replacement results in a stable compound. As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N).

[0034] Where there are nitrogen atoms in the compounds of the invention (e.g., amines), these atoms can be converted to N-oxides by treatment with an oxidizing agent (e.g., mCPBA and / or hydrogen peroxide) to provide other compounds of the invention. Thus, a specified nitrogen atom is considered to cover both the specified nitrogen and its N-oxide (N→O) derivative.

[0035] When any variable occurs more than one time in a constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is defined as being substituted with 0-3 R groups, then that group may be optionally substituted with up to 3 R groups, each R being independently selected from the definitions of R.

[0036] When a bond to a substituent is shown across a bond connecting two atoms in a ring, then such substituent may be bonded to any atom of the ring. When substituents are listed without indicating the atom to which such substituent is bonded to the remainder of a compound of a given formula, then such substituent may be bonded through any atom in such substituent.

[0037] Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0038] The term "pharmacologically acceptable" is used herein to refer to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response and / or other problem or complication, and in consideration of a reasonable benefit / risk ratio.

[0039] As used herein, "pharmaceutical acceptable salts" refers to derivatives of the disclosed compounds, where the parent compound is modified by making its acid or base salt. Examples of pharmaceutical acceptable salts include, but are not limited to, inorganic or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic or organic acids. Examples of pharmaceutical acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphosulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, and the like. Examples of suitable salts include esters, lactobionates, lactates, laurates, lauryl sulfates, malates, maleates, malonates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, oxalates, palmitates, pamoates, pectinates, persulfates, 3-phenylpropionates, phosphates, pivalates, propionates, stearates, succinates, sulfates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates, valerates, and the like.

[0040] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate with counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl and aryl sulfonates, and the like.

[0041] The pharma- ceutically acceptable salts of the present invention can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods. In general, such salts can be prepared by reacting the free acid or base of these compounds with a stoichiometric amount of a suitable base or acid in water or an organic solvent, or in a mixture of the two solvents; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. A list of suitable salts is described in Remington: The Science and Practice of Pharmacy, 22nd Edition, Pharmaceutical Press, London, UK (2012), edited by Allen, Jr., LV, the disclosure of which is incorporated herein by reference.

[0042] In addition, the compounds of formula I may be in the form of prodrugs. Any compound that will be converted in vivo to provide a biologically active drug (i.e., a compound of formula I) is a prodrug within the scope and spirit of the present invention. Various forms of prodrugs are well known in the art. Examples of such prodrug derivatives include: a) Bundgaard, H., ed., Design of Prodrugs, Elsevier (1985), and Widder, K. et al., eds., Methods in Enzymology, 112:309-396, Academic Press (1985); b) Bundgaard, H., Chapter 5, "Design and Application of Prodrugs," in Krosgaard-Larsen, P. et al., eds., A Textbook of Drug Design and Development, pp. 113-191, Harwood Academic Publishers (1991); c) Bundgaard, H., Adv. Drug Deliv. Rev., 8:1-38(1992); d) Bundgaard, H. et al., J. Pharm. Sci., 77:285(1988); e) Kakeya, N. et al., Chem. Pharm. Bull., 32:692 (1984); and f)Rautio, J., ed., Prodrugs and Targeted Delivery(Methods and Principles in Medicinal Chemistry), Vol. 47, Wiley-VCH(2011) Please refer to.

[0043] Compounds containing a carboxy group may form physiologically hydrolyzable esters that serve as prodrugs, hydrolyzed in the body to provide the compounds of formula I per se. Such prodrugs are often preferably administered orally, since hydrolysis occurs primarily under the influence of digestive enzymes. Parenteral administration may also be utilized in cases where the ester itself is active, or where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula I include C 1-6 Alkyl, C 1-6 Alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C 1-6 Alkanoyloxy C 1-6 Alkyl (e.g., acetoxymethyl, pivaloyloxymethyl, or propionyloxymethyl), C 1-6 Alkoxycarbonyloxy C 1-6Included are alkyl (e.g., methoxycarbonyloxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl) and other well-known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.

[0044] The preparation of prodrugs is well known in the art and is described, for example, in King, FD, ed., Medicinal Chemistry: Principles and Practice, The Royal Society of Chemistry, Cambridge, UK (2nd Edition, Reprint (2006)); Testa, B. et al., Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology, VCHA and Wiley-VCH, Zurich, Switzerland (2003); Wermuth, CG, ed., The Practice of Medicinal Chemistry, 3rd Edition, Academic Press, San Diego, CA (2008).

[0045] The present invention is intended to include all isotopes of atoms occurring in such compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, an isotope of hydrogen is deuterium (symbol D or 2 H) and tritium (symbol T or 3 For example, the methyl group can be represented as CH3 or CD3. The isotopes of carbon are 13 C and 14Isotopically labeled compounds of the invention can generally be prepared by common techniques known to those of skill in the art, or by methods analogous to those described herein, substituting appropriately isotopically labeled reagents for the unlabeled reagents otherwise used.

[0046] The term "solvate" refers to a physical association of the compound of the present invention with one or more solvent molecules, either organic or inorganic. This physical association includes hydrogen bonding. In certain cases, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. The solvent molecules in the solvate may be present in an ordered and / or non-ordered arrangement. The solvate may contain either stoichiometric or non-stoichiometric amounts of the solvent molecules. "Solvate" includes both liquid phase and isolable solvates. Examples of solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.

[0047] As used herein, the terms "measurable affinity" and "measurably inhibit" refer to a measurable change in the activity of PAD4 between a compound or composition thereof of the present invention and a sample containing PAD4, and an equivalent sample containing PAD4 without the compound or composition thereof.

[0048] Abbreviations used herein are defined as follows: "1x" is once, "2x" is twice, "3x" is three times, "°C" is degrees Celsius, "eq" is equivalent, "g" is grams, "mg" is milligrams, "L" is liters, "mL" is milliliters, "μL" is microliters, "N" is normality, "M" is moles, "mmol" is millimoles, "min" is minutes, "h" is hours, "rt" is room temperature, "RT" is retention time, "atm" is atmospheric pressure, "psi" is pounds per square inch, "conc." is concentrated, "aq" is aqueous, "sat" or "sat'd" is saturated, "MW" is molecular weight, "mp" is melting point, and "MS" or "Mass" is abbreviations. "Spec" is mass spectrometry, "ESI" is electrospray ionization mass spectrometry, "HR" is high resolution, "HRMS" is high resolution mass spectrometry, "LCMS" is liquid chromatography mass spectrometry, "HPLC" is high pressure liquid chromatography, "RP HPLC" is reversed phase HPLC, "TLC" or "tlc" is thin layer chromatography, "NMR" is nuclear magnetic resonance spectroscopy, "nOe" is nuclear Overhauser effect spectroscopy, 1 "H" is defined as proton, "δ" as delta, "s" as singlet, "d" as doublet, "t" as triplet, "q" as quartet, "m" as multiplet, "br" as broad, and "Hz" as Hertz, and "α", "β", "R", "S", "E", "Z" and "ee" are stereochemical designations well known to those of skill in the art. As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals, within the scope of sound medical judgment, without undue toxicity, irritation, allergic response, and the like, and having a reasonable benefit / risk ratio. [Table 1] [Table 2]

[0049] 3. Description of exemplary compounds In a first aspect, the present invention provides a compound of formula (I): [ka] [In formula: Q is selected from N and CH; Ring A is a 4- to 15-membered heterocyclyl substituted with 1 to 4 R7; R1 is selected from CH3 and CD3; R2 is H, 0 to 5 R e C replaced by 1-3 Alkyl and 0 to 5 R e C replaced by 3-6 cycloalkyl; R3 is H, F, Cl, Br, -OR b , and 0 to 5 R e C replaced by 1-3 selected from alkyl; L is absent or -NR d -, -O-, -C(=O)NR d - and -S(O) p -More selected; R4 is -(CH2) r -aryl substituted with 1 to 5 R5, -(CH2) r -C substituted with 1 to 5 R5 3-12 Cycloalkyl, -(CH2) r - heterocyclyl containing a carbon atom and 1-3 heteroatoms consisting of N, NR6, O and S, and substituted with 1-5 R5; R5 is H, F, Cl, Br, CN, nitro, 0 to 5 R e C replaced by 1-4 Alkyl, 0 to 5 R e C replaced by 2-4 Alkenyl, 0 to 5 R e C replaced by 2-4 Alkynyl, -(CHR d ) r OR b , -(CHR d ) r S(O) p R c , -(CHR d ) r S(O) p NRa R a , -(CHR d ) r NR a S(O) p R c , -(CHR d ) r NR a R a , -(CHR d ) r NR a C(=O)R b , -(CHR d ) r NR a C(=O)OR b , -(CHR d ) r NR a C(=O)NR a R a , -(CHR d ) r C(=O)R b , -(CHR d ) r C(=O)OR b , -(CHR d ) r C(=O)NR a R a , -(CHR d ) r OC(=O)R b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -C(=O)OR b , -C(=O)(CH2) r NR a R a , -S(O) p NR a R a , -(CH2) r -0 to 4 Re C replaced by 3-6 Cycloalkyl, -(CH2) r -0 to 4 R e Aryl substituted with -(CH2) r -0 to 4 R e heterocyclyl substituted with; R7 is H, F, Cl, CN, C 1-3 Alkyl, =N-OR b , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=NH)C 1-3 Alkyl, -NR a C(=O)OR b , carbocycle, and heterocycle; or alternatively, two R7 groups taken together form a carbocycle or heterocycle; R8 is H, F, Cl, Br, or 0 to 5 R e C replaced by 1-4 independently selected from alkyl; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 Re C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are each H and 0 to 5 R e C replaced by 1-6 independently selected from alkyl; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -aryl, Si(C 1-4 Alkyl)3, F, Cl, Br, CN, NO2, =O, CO2H, -(CH2) r OR f , S(O) p R f , C(=O)NR f R f , S(O) p NR f R f , and -(CH2)r NR f R f more independently selected; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 3-6 cycloalkyl, and phenyl; or R f and R f Together with the nitrogen atom to which they are both attached, 1-4 forming a heterocyclic ring which may be optionally substituted with alkyl; each p is independently selected from 0, 1, and 2; Each r is independently selected from 0, 1, 2, 3, and 4; however: (1) If L is absent, R4 is [ka] is a group other than (2) L is -NR d -, then R4 is [ka] is a group other than (3) When L is -O-, R4 is C 3-6 is a group other than cycloalkyl. or a pharma- ceutically acceptable salt thereof.

[0050] In a second aspect, the present invention provides, within the scope of the first aspect, Ring A is [ka] More selected; R1 is selected from CH3 and CD3; R2 is methyl, ethyl, or -CH2-0 to 3 R ecyclopropyl substituted with; R3 is H, F, Cl, Br, and -OC 1-4 selected from alkyl; L is absent or -NR d selected from -, -O-, -C(=O)NH-, -S-, and -S(O)2-; R4 is [ka] [ka] [ka] [ka] More selected; R5 is H, F, Cl, Br, CN, or 0 to 5 R e C replaced by 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -(CHR d ) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2)r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r OC(=O)R b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -C(=O)(CH2) r NR a R a , -C(=O)OR b , -S(O) p NR a R a , -(CH2) r -0 to 4 R e Aryl substituted with -(CH2) r -0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or Ra and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are each H and 0 to 5 R e C replaced by 1-6 independently selected from alkyl; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4. or a pharma- ceutically acceptable salt thereof.

[0051] In a third aspect, the present invention provides a compound of formula (II): [ka] [In formula: Ring A is [ka] More selected; R2 is selected from methyl and -CH2-cyclopropyl; R3 is H, F, and -OC 1-4 selected from alkyl; R4 is [ka] [ka] More selected; R5 is H, F, Cl, Br, CN, or 0 to 4 R e C replaced by 1-4 Alkyl, -(CHR d ) r OR b , -S(O) p Rc , -S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -NR a C(=O)OR b , -NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -(CH2) r -C(=O)NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -C(=O)OR b , -S(O) p NR a R a , 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R eheterocyclyl substituted with; R d are each H and 0 to 5 R e C replaced by 1-6 independently selected from alkyl; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4. or a pharma- ceutically acceptable salt thereof.

[0052] In a fourth aspect, the present invention provides a compound of formula (III): [ka] [In formula: Ring A is [ka] and; R2 is -CH2-cyclopropyl; R3 is -OC1-4 is alkyl; R5 is H, F, Cl, Br, CN, or 0 to 4 R e C replaced by 1-4 Alkyl, -(CHR d ) r OR b , -S(O) p R c , -(CH2) r NR a R a , -(CH2) r NHC(=O)R b , -NHC(=O)OR b , -(CH2) r NHS(O) p R c , -(CH2) r C(=O)NR a R a , -(CH2) r C(=O)OR b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 Re C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are H and C, respectively. 1-6 independently selected from alkyl; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, -(CH2) r O.C. 1-4 Alkyl, and SO2C1-4 independently selected from alkyl; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4. or a pharma- ceutically acceptable salt thereof.

[0053] In a fifth aspect, the present invention provides, within the scope of the fourth aspect, R3 is -OCH3; and R5 is H, F, Cl, Br, C 1-4 Alkyl, -OH, -OC 1-3 Alkyl, and -NHS(O)2C 2-4 alkenyl, A compound or a pharma- ceutically acceptable salt thereof is provided.

[0054] In a sixth aspect, the present invention provides, within the scope of the third aspect, Ring A [ka] and; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R4 [ka] More selected; R5 is H, F, Cl, Br, CN, 0 to 4 R e C replaced by 1-4 Alkyl, -(CH2) r OR b , -S(O) p R c , -S(O)p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -NR a C(=O)OR b , -NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R feach of which is optionally substituted with H, F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0055] In a seventh aspect, the present invention relates to a method for producing a composition comprising the steps of: R3 is -OCH3; and R5 is H, F, Cl, Br, C 1-4 Alkyl, -OH, -OC 1-3 Alkyl, and -NHS(O)2C 2-4 alkenyl, A compound or a pharma- ceutically acceptable salt thereof is provided.

[0056] In an eighth aspect, the present invention provides, within the scope of the third aspect, Ring A [ka] and; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R4, [ka] More selected: R5 is H, F, Cl, Br, CN, C 1-4 Alkyl, -OR b , -S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -NRa C(=O)OR b , -(CH2) r NR a S(O) p R c , -C(=O)NR a R a , -C(=O)OR b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -(CH2) r -C(=O)NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -C(=O)OR b , -S(O) p NR a R a , 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R aThe nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2)r O.C. 1-4 independently selected from alkyl; R f each of which is optionally substituted with H, F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0057] In a ninth aspect, the present invention relates to a method for producing a composition comprising the steps of: R4, [ka] More selected: R5 is H, F, Cl, Br, C 1-4 alkyl, and OH; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0058] In a tenth aspect, the present invention relates to a compound according to the ninth aspect, comprising a compound of formula (IV): [ka] [In formula: Ring A is [ka] and; R2 is selected from methyl and -CH2-cyclopropyl; R3 is H, F, and -OC 1-4 selected from alkyl; R4 is [ka] More selected; R5 is H, F, Cl, Br, CN, C 1-4 Alkyl, -(CH2) r OR b , -NR a R a , -NR a C(=O)R b , -NR a C(=O)OR b , -C(=O)OR b , N.R. a S(O) p R c , -C(=O)NR a R a , -NR a C(=O)NR a R a , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H and C 1-3 independently selected from alkyl; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r-0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are H and C, respectively. 1-3 independently selected from alkyl; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4. or a pharma- ceutically acceptable salt thereof.

[0059] In an eleventh aspect, the present invention relates to a method for producing a composition comprising the steps of: R2 is -CH2-cyclopropyl; R3 is -OCH3; R4 [ka] and; R5 is H, F, Cl, Br, C 1-4 Alkyl, and -(CH2) 0-1 OH; and R d is H, A compound or a pharma- ceutically acceptable salt thereof is provided.

[0060] In a twelfth aspect, the present invention relates to a method for producing a composition comprising the steps of: L is -C(=O)NH-; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R4, [ka] More selected; R5 is H, F, Cl, Br, C 1-4 is independently selected from alkyl, -OH, and -CN; and R6 is H and C 1-3 independently selected from alkyl, A compound or a pharma- ceutically acceptable salt thereof is provided.

[0061] In a thirteenth aspect, the present invention relates to a method for the preparation of a composition comprising the steps of: L is -O-; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R4, [ka] selected from; and R5 is H, F, Cl, Br, C 1-4 independently selected from alkyl, -OH, and -CN; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0062] In a fourteenth aspect, the present invention relates to a compound of formula (I): [ka] [In formula: Q is selected from N and CH; Ring A is a 4- to 15-membered heterocyclyl substituted with 1 to 4 R7; R1 is CH3, CD3, and -CH2- carbon atoms and N, NC 1-4 5-membered heterocyclyl containing 1 to 3 heteroatoms selected from alkyl, O, and S; R2 is H, 0 to 5 R e C replaced by 1-3 Alkyl, and -(CH2) r -0 to 5 R e C replaced by 3-6 cycloalkyl; R3 is H, F, Cl, Br, -OR b , and 0 to 5 R e C replaced by 1-3 selected from alkyl; L is absent or -NR d -, -O-, -C(=O)NR d - and -S(O) p -More selected; R4 is -(CH2) r -aryl substituted with 1 to 7 R5, -(CH2) r -C 3-12 Cycloalkyl (1 to 2 ORb , C(=O)OR b , -C(=O)NR a R a , -NR a C(=O)R b substituted with 1 to 7 R5), containing a carbon atom and 1 to 3 heteroatoms selected from N, NR6, O and S, -(CH2) r -heterocyclyl; R5 is H, F, Cl, Br, CN, =O, nitro, 0 to 5 R e C replaced by 1-4 Alkyl, 0 to 5 R e C replaced by 2-4 Alkenyl, 0 to 5 R e C replaced by 2-4 Alkynyl, -(CHR d ) r OR b , -(CHR d ) r S(O) p R c , -(CHR d ) r S(O) p NR a R a , -(CHR d ) r NR a S(O) p R c , -(CHR d ) r NR a R a , -(CHR d ) r NR a C(=O)R b , -(CHR d ) r NR a C(=O)OR b , -(CHR d ) r NR a C(=O)NR a R a , -(CHR d ) r C(=O)R b , -(CHR d )r C(=O)OR b , -(CHR d ) r C(=O)NR a R a , -(CHR d ) r OC(=O)R b , -(CHR d ) r OC(=O)OR b , -(CHR d ) r O(CH2) r C(=O)NR a R a , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -(CH2) r C(=O)R b , -(CH2) r -C(=O)OR b , -(CH2) r C(=O)(CH2) r NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -S(O) p NR a R a , -(CH2) r -0 to 4 R e C replaced by 3-6 Cycloalkyl, -(CH2) r -0 to 4 R e Aryl substituted with -(CH2) r -0 to 4 R e heterocyclyl substituted with; R7 is H, F, Cl, CN, C 1-3 Alkyl, =N-ORb , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=NH)C 1-3 Alkyl, -NR a C(=O)OR b , carbocyclyl, and heterocyclyl; alternatively, two R7 groups taken together form a carbocyclyl or heterocyclyl; R8 is H, F, Cl, Br, or 0 to 5 R e C replaced by 1-4 independently selected from alkyl; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R eheterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are H and 0 to 5 R e C replaced by 1-6 alkyl, and OH; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -aryl, -(CH2) r -heterocyclyl, Si(C 1-4 Alkyl)3, F, Cl, Br, CN, NO2, =O, CO2H, -(CH2) r OR f , S(O) p R f , C(=O)NR f R f , S(O) p NR f R f , and -(CH2) r NR f R f more independently selected; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 2-5 Alkenyl, C 2-5Alkynyl, C 3-6 cycloalkyl, and phenyl; or R f and R f Together with the nitrogen atom to which they are both attached, 1-4 forming a heterocyclic ring which may be optionally substituted with alkyl; each p is independently selected from 0, 1, and 2; Each r is independently selected from 0, 1, 2, 3, and 4; however: (1) If L is absent, R4 is [ka] is a group other than (2) L is -NR d -, then R4 is [ka] is a group other than (3) When L is -O-, R4 is C 3-6 is a group other than cycloalkyl. or a pharma- ceutically acceptable salt thereof.

[0063] In a fifteenth aspect, the present invention relates to a method for producing a composition comprising the steps of: [ka] but [ka] More selected; R1 is selected from CH3 and CD3; R2 is methyl, ethyl, or -CH2-0 to 3 R e cyclopropyl substituted with; R3 is H, F, Cl, Br, and -OC 1-4 selected from alkyl; L is absent or -NR dselected from -, -O-, -C(=O)NH-, -S-, and -S(O)2-; R4 is 1 to 4 of F, Cl, OH, and C 3-6 Cycloalkyl-substituted C 1-5 Alkyl, [ka] [ka] [ka] [ka] More selected; R5 is H, F, Cl, Br, CN, =O, 0 to 5 R e C replaced by 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -(CHR d ) r OR b , -(CH2) r S(O) p R c , -(CH2) r S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -(CH2) r NR a C(=O)OR b , -(CH2) r NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)ORb , -(CHR d ) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)(CH2) r NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -S(O) p NR a R a , 0 to 4 R e Substituted with -(CH2) r -aryl, and 0 to 4 R e Substituted with -(CH2) r -heterocyclyl; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r-0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are H and 0 to 5 R e C replaced by 1-6 alkyl, and OH; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -aryl, -(CH2) r -Heterocyclyl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R f each of which is optionally substituted with H, F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0064] In a sixteenth aspect, the present invention provides, within the scope of the fifteenth aspect, a compound of formula (II): [ka] [In formula: [ka] teeth [ka] More selected; R2 is selected from CH3, CH2CH3, and -CH2-cyclopropyl substituted with 0-2 F, Cl, and CH3; R3 is H, F, and -OC 1-4 selected from alkyl; R4 is 1 to 4 of F, OH, and C. 3-6Cycloalkyl-substituted C 1-4 Alkyl, [ka] [ka] [ka] More selected; R5 is H, F, Cl, Br, CN, =O, or 0 to 4 R e C replaced by 1-4 Alkyl, -(CHR d ) r OR b , -(CH2) r -S(O) p R c , -S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -NR a C(=O)OR b , -NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CHR d ) r C(=O)NR a R a , -(CH2) r OC(=O)R b , -(CH2) r OC(=O)OR b , -(CH2) r O(CH2) r C(=O)NR a R a, 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -S(O) p NR a R a , 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are each H and 0 to 5 R e C replaced by 1-6 independently selected from alkyl; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -aryl, -(CH2) r -Heterocyclyl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C.1-4 independently selected from alkyl; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4; or a pharma- ceutically acceptable salt thereof.

[0065] In a seventeenth aspect, the present invention relates to a compound according to the sixteenth aspect, comprising a compound of formula (III): [ka] [In formula: [ka] teeth [ka] More selected; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R5 is H, F, Cl, Br, CN, or 0 to 4 R e C replaced by 1-4 Alkyl, -(CHR d ) r OR b , -(CH2) r S(O) p R c , -S(O) p NR a R a , -(CH2) r NHS(O) p R c , -(CH2) r NR a R a , -(CH2) r NHC(=O)Rb , -NHC(=O)OR b , -(CHR d ) r C(=O)NR a R a , -(CH2) r C(=O)OR b , -OC(=O)OR b , -O(CH2) 0-1 C(=O)NR a R a , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R d are H and C, respectively. 1-4 alkyl, and OH; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -aryl, -(CH2) r -Heterocyclyl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, -(CH2) r O.C. 1-4 Alkyl, and SO2C 1-4 independently selected from alkyl; R f each is H, F, Cl, Br, CN, OH, C optionally substituted with OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1, and 2; and each r is independently selected from 0, 1, 2, 3, and 4; or a pharma- ceutically acceptable salt thereof.

[0066] In an eighteenth aspect, the present invention relates to a method for producing a composition comprising the steps of: R3 is -OCH3; R5 is H, F, Cl, Br, CN, C 1-4 Alkyl, -(CH2) 0-1 OR b , -S(O)2NH2, -NHS(O)2C 1-3 Alkyl, -NHS(O)2C 2-4 Alkenyl, -NHC(=O)R b , -C(=O)NH2, and [ka] and heterocyclyl selected from: R b Each of them is H and 0 to 5 R e C replaced by 1-6 independently selected from alkyl; R e However, each 1-6 Alkyl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, -(CH2) r O.C. 1-4 Alkyl, and SO2C 1-4 independently selected from alkyl, A compound or a pharma- ceutically acceptable salt thereof is provided.

[0067] In a nineteenth aspect, the present invention relates to a method for producing a composition comprising the steps of: [ka] but [ka] More selected; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R4, [ka] More selected; R5 is H, F, Cl, Br, CN, 0 to 4 R e C replaced by 1-4 Alkyl, -(CH2) r OR b , -S(O) p R c , -S(O) p NR a R a , -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -NR a C(=O)OR b , -NR a C(=O)NR a R a , -(CH2) r C(=O)R b , -(CH2) r C(=O)OR b , -(CH2) r C(=O)NR a R a , -(CH2) r OC(=O)R b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; R b are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R eheterocyclyl substituted with; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R f each of which is optionally substituted with H, F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3, and 4; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0068] In a twentieth aspect, the present invention relates to a method for producing a composition comprising the steps of: R3 is -OCH3; R5 is H, F, Cl, Br, C 1-4 Alkyl, -OH, -OC 1-3 Alkyl, -NHS(O)2C 2-4 Alkenyl, NHC(=O)OC 1-4 Alkyl, C(=O)NH2, C(=O)NHC 1-4 Alkyl, and [ka] and Re However, each 1-6 Alkyl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, -(CH2) r O.C. 1-4 Alkyl, and SO2C 1-4 independently selected from alkyl, A compound or a pharma- ceutically acceptable salt thereof is provided.

[0069] In a twenty-first aspect, the present invention relates to a method for producing a composition comprising the steps of: [ka] but [ka] More selected; R2 is -CH2-cyclopropyl; R3 is -OC 1-4 is alkyl; R4, [ka] [ka] More selected; R5 is H, F, Cl, Br, CN, C 1-4 Alkyl, -OR b , -S(O) p R c -(CH2) r NR a S(O) p R c , -(CH2) r NR a R a , -(CH2) r NR a C(=O)R b , -NR a C(=O)ORb , -C(=O)OR b , C(=O)NR a R a , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with heterocyclyl substituted with; R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -C(=O)OR b , -(CH2) r -C(=O)NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -S(O) p NR a R a , 0 to 4 R e Aryl substituted with, and 0 to 4 R e heterocyclyl substituted with; R a are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e or R a and R a The nitrogen atom to which both are bonded and the nitrogen atom to which they are bonded together form 0 to 5 R e forming a heterocyclic ring substituted with; Rb are H and 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, -(CH2) r -0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-10 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R c Each has 0 to 5 R e C replaced by 1-6 Alkyl, 0 to 5 R e C replaced by 2-6 Alkenyl, 0 to 5 R e C replaced by 2-6 Alkynyl, -(CH2) r -0 to 5 R e C replaced by 3-6 Carbocyclyl, and -(CH2) r -0 to 5 R e heterocyclyl substituted with; R e Each has 0 to 5 R f C replaced by 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) r -C 3-6 Cycloalkyl, -(CH2) r -Aryl, F, Cl, Br, CN, NO2, =O, -NH2, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2, -C(=O)OH, -C(=O)OC 1-4 Alkyl, -(CH2) r OH, and -(CH2) r O.C. 1-4 independently selected from alkyl; R feach of which is optionally substituted with H, F, Cl, Br, CN, OH, OH 1-5 Alkyl, C 3-6 cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3, and 4; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0070] In a twenty-second aspect, the present invention relates to a method for producing a composition comprising the steps of: R4, [ka] selected from; and R5 is H, F, Cl, Br, C 1-4 independently selected from alkyl, OH, and -C(=O)OH; A compound or a pharma- ceutically acceptable salt thereof is provided.

[0071] In a twenty-third aspect, the present invention relates to a compound of formula (V): [ka] [In formula: [ka] teeth [ka] More selected; R2 is -CH2-cyclopropyl; R3 is -OCH3; and R4 is [ka] Selected from or a pharma- ceutically acceptable salt thereof.

[0072] In a twenty-fourth aspect, the present invention relates to a compound of formula (VI): [ka] [In formula: [ka] teeth [ka] More selected; R2 is -CH2-cyclopropyl; R4 is [ka] selected from; and R5 is selected from H, OH, CH2OH, and -C(CH3)2OH. or a pharma- ceutically acceptable salt thereof.

[0073] In a twenty-fifth aspect, the present invention relates to a compound of formula (VII): [ka] [In formula: [ka] teeth [ka] More selected; R2 is -CH2-cyclopropyl; R4 is [ka] Selected from R5 is F, Cl, C 1-4 Alkyl, -(CH2) r OR b , -S(O)NR a R a , -NR a S(O)2Rc , and -C(=O)NR a R a more independently selected; R6 is H and C 1-3 independently selected from alkyl; R a are each H and 0 to 5 R e C replaced by 1-4 independently selected from alkyl; R b are each H and 0 to 5 R e C replaced by 1-4 independently selected from alkyl; R c each independently represents 0 to 5 R e C replaced by 1-4 is alkyl; R e are F, Cl, Br, -OH, and -OC, respectively. 1-4 alkyl; and each r is independently selected from 0, 1, and 2; or a pharma- ceutically acceptable salt thereof.

[0074] In one embodiment, the present invention relates to a compound that is capable of inhibiting a cytotoxic T cell death by administering an IC50 value to a patient using the RFMS PAD4 functional assay disclosed herein. < Preferably with an IC50 value of 4.000 μM < Preferably with an IC50 value of 1.000 μM < Preferably with an IC50 value of 0.500 μM < More preferably, an IC50 value of 0.100 μM < Preferably with an IC50 value of 0.050 μM < Preferably with an IC50 value of 0.03 μM < and even more preferably an IC50 value of 0.02 μM. < 0.01 μM of compound is provided.

[0075] As defined above and described herein, R1 is selected from CH3 and CD3. In some embodiments, R1 is CH3. In some embodiments, R1 is CD3.

[0076] R2 is hydrogen and 0 to 5 R e C replaced by 1-3 Alkyl or 0 to 5 R e C replaced by 3-6 In some embodiments, R2 is cycloalkyl. In some embodiments, R2 is hydrogen. In some embodiments, R2 is C 3-6 Cycloalkyl-substituted C 1-2 In some embodiments, R2 is C 3-6 In some embodiments, R2 is cycloalkyl. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl. In some embodiments, R2 is cyclopropyl. In some embodiments, R2 is cyclobutyl. In some embodiments, R2 is cyclopentyl. In some embodiments, R2 is cyclohexyl. In some embodiments, R2 is cyclopropylmethyl. In some embodiments, R2 is cyclobutylmethyl. In some embodiments, R2 is cyclopentylmethyl. In some embodiments, R2 is cyclohexylmethyl. In some embodiments, R2 is cyclopropylethyl. In some embodiments, R2 is cyclobutylethyl. In some embodiments, R2 is cyclopentylethyl. In some embodiments, R2 is cyclohexylethyl. In some embodiments, R2 is -CH2-cyclopropyl or -CH2-cyclobutyl. In some embodiments, R2 is -CH2-cyclobutyl optionally substituted with methyl and -OH. In some embodiments, R2 is selected from those functional groups described in the examples below.

[0077] As defined above and described herein, Q is N or CH. In some embodiments, Q is N. In some embodiments, Q is CH. In some embodiments, Q is selected from those functional groups described in the examples below.

[0078] R3 is H, F, Cl, Br, -OR, as defined above and described herein. b , and 0 to 5 R e C replaced by 1-3 In some embodiments, R3 is selected from alkyl. In some embodiments, R3 is H. In some embodiments, R3 is F, Cl, Br. In some embodiments, R3 is F. In some embodiments, R3 is C 1-3 In some embodiments, R3 is alkyl. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl. In some embodiments, R3 is propyl. In some embodiments, R3 is OR b In some embodiments, R3 is -OCH3. In some embodiments, R3 is -OCH2CH3. In some embodiments, R3 is -OCH2CH2CH3. In some embodiments, R3 is -OCH(F)2. In some embodiments, R3 is selected from those functional groups described in the examples below.

[0079] L is absent, -NR d -, -O-, -C(=O)NR d - or -S(O) p in some embodiments, L is -NR d - and R d is H or C 1-3In some embodiments, L is -alkyl. In some embodiments, L is -O-. In some embodiments, L is -C(=O)NH-. In some embodiments, L is -S(O)2-. In some embodiments, L is -S-. In some embodiments, L is selected from those functional groups described in the examples below.

[0080] As defined above and described herein, R4 is each [ka] [ka] It is.

[0081] In some embodiments, R4 is [ka] In some embodiments, R4 is [ka] In some embodiments, R4 is [ka] In some embodiments, R4 is [ka] It is.

[0082] In some embodiments, R4 is [ka] It is.

[0083] In some embodiments, R4 is [ka] In some embodiments, R4 is [ka] In some embodiments, R4 is [ka] It is.

[0084] In some embodiments, R4 is [ka] It is.

[0085] In one embodiment, R4 is [ka] It is.

[0086] In one embodiment, R4 is [ka] It is.

[0087] In one embodiment, R4 is [ka] It is.

[0088] In one embodiment, R4 is [ka] It is.

[0089] In one embodiment, R4 is [ka] It is.

[0090] In some embodiments, R4 is selected from the group consisting of 1 to 4 of F, Cl, Br, OH, and C. 3-6 Cycloalkyl-substituted C 1-5 It is an alkyl.

[0091] In certain embodiments, R4 is [ka] is selected from.

[0092] R5 is H, F, Cl, Br, CN, 0-5 R e C replaced by 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, nitro, -S(O) p R c , -S(O) p NR a R a , -NR a S(O) p R c , -(CH2) r OR b , -(CH2) r NR a R a , -NR a C(=O)R b , N.R. a C(=O)OR b , -NR a C(=O)NR a R a , -C(=O)R b , -C(=O)OR b , C(=O)NR a R a , -OC(=O)R b , 0 to 4 R e C replaced by 3-6 Cycloalkyl, 0 to 4 R e Aryl substituted with, and 0 to 4 R e is a heterocyclyl substituted with

[0093] In some embodiments, R5 is H, F, Cl, CN, C1-4 Alkyl, C 1-4 Alkyl (substituted with OH, NH2, and COOH), SC 1-4 Alkyl, -S(O)C 1-4 Alkyl, S(O)2NH-Cyclopropyl, -(CH2) 0-1 NHS(O)2C 1-4 Alkyl, -N(R d )S(O)2C 2-4 Alkenyl, -(CH2) 0-1 OH, O.C. 1-4 Alkyl, -(CH2) 0-1 NH2, -(CH2) 0-1 NHC(=O)C 1-4 Alkyl, -NR d C(=O)C 2-4 Alkenyl, -NHC(=O)C 2-4 Alkynyl, -(CH2) 0-1 C(=O)OH, -C(=O)OC 1-4 Alkyl, -NHC(=O)OC 1-4 Alkyl, -NHC(=O)O(CH2)2OC 1-4 Alkyl, -NHC(=O)OCH2-Cyclopropyl, -NHC(=O)NH2, C(=O)NHC 1-4 Alkyl, CONH(CH2) 1-2 C(=O)OH, -(CH2) 0-1 C(=O)NH2, -(CH2) 0-1 C(=O)NHC 1-4 Alkyl, C(=O)NH-pyridine, -C(=O)NH(CH2)2N(C 1-4 alkyl)2, -C(=O)NH(CH2)2OH, -C(=O)NH(CH2)2S(O)2C 1-4 Alkyl, and -OC(=O)C 1-4 It is an alkyl.

[0094] In some embodiments, R5 is [ka] It is. In some embodiments, R5 is [ka] It is.

[0095] In some embodiments, R5 is F. In some embodiments, R5 is C 1-4 In some embodiments, R5 is -OH or -OC 1-3 In some embodiments, R5 is -NHS(O)2C 2-4 alkenyl. In certain embodiments, R5 is selected from those groups described in the examples below.

[0096] R6 is H, 0 to 4 R e C replaced by 1-3 Alkyl, -S(O) p R c , -C(=O)R b , -(CH2) r -C(=O)NR a R a , -C(=O)(CH2) r NR a C(=O)R b , -C(=O)OR b , -S(O) p NR a R a , 0 to 4 R e or 0 to 4 R e is a heterocyclyl substituted with

[0097] In some embodiments, R6 is H. In some embodiments, R6 is methyl or isopropyl. In some embodiments, R6 is -(CH2)2C(=O)NH2. In some embodiments, R6 is -(CH2)2OH. In some embodiments, R6 is C(=O)C 1-4 In some embodiments, R6 is selected from those groups described in the examples below.

[0098] R7 is H, F, Cl, C as defined above and described herein. 1-3 Alkyl, -NR a R a , or -NR a C(=O)OR b In some embodiments, R7 is NH2. In some embodiments, R7 is F.

[0099] R8 is H, F, Cl, Br, or 0-5 R e C replaced by 1-4 In some embodiments, R is H. In some embodiments, R is C 1-3 It is an alkyl.

[0100] As defined above, ring A is [ka] It is.

[0101] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0102] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0103] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0104] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0105] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0106] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] It is.

[0107] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In some embodiments, ring A is [ka] In certain embodiments, R4 is selected from those functional groups described in the examples below.

[0108] As defined above and described herein, r is 0 to 4. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] and R5 is H, F, Cl, CN, C 1-4 C substituted with alkyl, OH, NH2 and COOH 1-4 Alkyl, SC 1-4 Alkyl, -S(O)C 1-4 Alkyl, S(O)2NH-Cyclopropyl, -(CH2) 0-1 NHS(O)2C 1-4 Alkyl, -N(R d )S(O)2C 2-4 Alkenyl, -(CH2) 0-1 OH, O.C. 1-4 Alkyl, -(CH2) 0-1 NH2, -(CH2) 0-1 NHC(=O)C 1-4 Alkyl, -NR d C(=O)C 2-4 Alkenyl, -NHC(=O)C 2-4 Alkynyl, -(CH2) 0-1 C(=O)OH, -C(=O)OC 1-4 Alkyl, -NHC(=O)OC 1-4 Alkyl, -NHC(=O)O(CH2)2OC 1-4 Alkyl, -NHC(=O)OCH2-Cyclopropyl, -NHC(=O)NH2, C(=O)NHC 1-4 Alkyl, CONH(CH2) 1-2 C(=O)OH, -(CH2) 0-1 C(=O)NH2, -(CH2) 0-1 C(=O)NHC 1-4 Alkyl, C(=O)NH-pyridine, -C(=O)NH(CH2)2N(C 1-4 alkyl)2, -C(=O)NH(CH2)2OH, -C(=O)NH(CH2)2S(O)2C 1-4 Alkyl, -OC(=O)C 1-4 Alkyl, [ka] It is.

[0109] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] and R5 is H, F, Cl, CN, C 1-4 C substituted with alkyl, OH, NH2 and COOH 1-4 Alkyl, SC 1-4 Alkyl, -S(O)C 1-4 Alkyl, S(O)2NH-Cyclopropyl, -(CH2) 0-1 NHS(O)2C 1-4 Alkyl, -N(R d )S(O)2C 2-4 Alkenyl, -(CH2) 0-1 OH, O.C. 1-4 Alkyl, -(CH2) 0-1 NH2, -(CH2) 0-1 NHC(=O)C 1-4 Alkyl, -NR d C(=O)C 2-4 Alkenyl, -NHC(=O)C 2-4 Alkynyl, -(CH2) 0-1 C(=O)OH, -C(=O)OC 1-4 Alkyl, -NHC(=O)OC 1-4 Alkyl, -NHC(=O)O(CH2)2OC 1-4 Alkyl, -NHC(=O)OCH2-Cyclopropyl, -NHC(=O)NH2, C(=O)NHC 1-4 Alkyl, CONH(CH2) 1-2 C(=O)OH, -(CH2) 0-1 C(=O)NH2, -(CH2) 0-1 C(=O)NHC 1-4 Alkyl, C(=O)NH-pyridine, -C(=O)NH(CH2)2N(C 1-4alkyl)2, -C(=O)NH(CH2)2OH, -C(=O)NH(CH2)2S(O)2C 1-4 Alkyl, -OC(=O)C 1-4 Alkyl, [ka] It is.

[0110] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] It is.

[0111] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] It is.

[0112] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] It is.

[0113] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] It is.

[0114] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] It is.

[0115] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] It is.

[0116] In some embodiments, ring A is [ka] where R1 is CH3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or -OCH3, and R4 is [ka] and R5 is H, F, C1-4 Alkyl, -OH, -OC 1-3 Alkyl and -NHS(O)2C 2-4 It is alkenyl.

[0117] In some embodiments, the compound of formula (I) is selected from the following examples. In some embodiments, the present invention provides any of the compounds described above and herein, or any pharma- ceutically acceptable salts thereof, or compositions for use in therapy. In some embodiments, the present invention provides any of the compounds described above and herein in isolated form. In some embodiments, the present invention provides any of the compounds described in any one of claims 1-16. 4. Use, Formulation and Administration Pharmaceutically acceptable compositions

[0118] According to another embodiment, the invention provides a composition comprising the compound of the present invention or its pharma- ceutical acceptable derivative and a pharma- ceutical acceptable carrier, adjuvant, or vehicle.The amount of the compound incorporated in the composition of the present invention is such that it is effective to appreciably inhibit PAD4 in biological samples or patients.In certain embodiments, the amount of the compound in the composition of the present invention is such that it is effective to visibly inhibit PAD4 in biological samples or patients.In certain embodiments, the composition of the present invention is formulated to be administered to a patient in need of such a composition.In some embodiments, the composition of the present invention is formulated to be administered orally to a patient.

[0119] As used herein, the term "subject" is used interchangeably with the term "patient" and refers to an animal, preferably a mammal. In some embodiments, the subject or patient is a human. In other embodiments, the subject (or patient) is a veterinary subject (or patient). In some embodiments, the veterinary subject (or patient) is a dog, cat or horse.

[0120] The term "pharmaceutical acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants, or vehicles that can be used with the compounds of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block copolymers, polyethylene glycol, and wool fat.

[0121] The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an implanted reservoir. The term "parenterally" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of the present invention may be aqueous or oily suspensions. These suspensions may be formulated using suitable dispersing or wetting agents and suspending agents according to techniques known in the art. Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as, for example, a solution of 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are commonly employed as solvents or suspending media.

[0122] For this purpose, any sterile fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful for preparing injections, as well as natural medicamentously acceptable oils such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, which are commonly used to formulate pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span and other emulsifiers or bioavailability enhancers, which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid or other dosage forms, may also be used for formulation purposes.

[0123] The pharma- ceutically acceptable composition of the present invention can be orally administered in any orally acceptable dosage form, including, but not limited to, capsule, tablet, aqueous suspension or solution.For oral tablets, commonly used carriers include lactose and corn starch.Lubricants such as magnesium stearate are also typically added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspension is required for oral use, active ingredient is combined with emulsifier and suspending agent.If necessary, certain sweeteners, flavorings or colorings can also be added.

[0124] Alternatively, the pharma- ceutically acceptable compositions of the present invention may be administered in the form of suppositories for rectal administration. These may be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will thus melt in the rectum and release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols.

[0125] The pharma- ceutically acceptable compositions of this invention may also be administered topically, particularly when the target of treatment includes areas or organs readily addressable by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0126] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[0127] For topical application, the pharma- ceutical acceptable composition provided may be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the pharma- ceutical acceptable composition provided may be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0128] For ophthalmic use, the pharma- ceutically acceptable compositions provided may be formulated as a microsuspension in isotonic, pH-adjusted, sterile saline, or, preferably, as a solution in isotonic, pH-adjusted, sterile saline, either with or without a preservative, such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharma-ceutically acceptable compositions may be formulated in an ointment, such as petrolatum.

[0129] The pharma- ceutically acceptable compositions of the present invention may also be administered by nasal aerosol or inhalation.Such compositions may be prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as a solution in saline utilizing benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0130] Most preferably, the pharma- ceutically acceptable compositions of the present invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharma- ceutically acceptable compositions of the present invention are administered without food. In other embodiments, the pharma- ceutically acceptable compositions of the present invention are administered with food.

[0131] The pharma- ceutically acceptable compositions of the present invention may be administered to humans and other animals orally, rectally, parenterally, intravesically, intravaginally, intraperitoneally, topically (such as by powders, ointments or drops), bucally, as oral or nasal sprays, etc., depending on the severity of the infection to be treated. In certain embodiments, the compounds of the present invention may be administered orally or parenterally at a dosage level of about 0.01 mg to about 50 mg, preferably about 1 mg to about 25 mg, per kg of subject body weight per day, once or several times a day to obtain the desired therapeutic effect.

[0132] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed, peanut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.Besides inert diluents, the oral compositions may also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, and aromatic agents.

[0133] Injectable preparations, for example, sterile injectable aqueous or oily suspensions, may be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, USP, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any sterile fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0134] Injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0135] In order to prolong the effect of the compounds of the present invention, it is often desirable to delay the absorption of the compounds from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends on its rate of dissolution, which in turn may depend on the crystal size and crystalline form. Alternatively, delayed absorption of parenterally administered compound forms can be achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are prepared by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the properties of the particular polymer employed, the release rate of the compound can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by encapsulating the compound in liposomes or microemulsions that are compatible with body tissues.

[0136] Compositions for rectal or vaginal administration are preferably suppositories which may be prepared by mixing the compounds of the present invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol or a suppository wax, which is solid at ambient temperature but liquid at body temperature and thus melts in the rectal or vaginal cavity and releases the active compound.

[0137] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharma- ceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) hygroscopic agents, such as glycerol; d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents, such as paraffin; f) absorption accelerators, such as quaternary ammonium compounds; g) humectants, such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents, such as kaolin and bentonite clay; i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0138] Solid compositions of similar type may also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. They may optionally contain opacifying agents, and they may also be of a composition that releases the active ingredient only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be used include polymeric substances and waxes. Solid compositions of similar type may also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols.

[0139] The active compound may also be in microencapsulated form with one or more of the excipients mentioned above. The solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings well known in the field of pharmaceutical formulation. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. Such dosage forms may also contain additives other than inert diluents, such as tablet lubricants and other tableting aids, as is the current normal practice. In the case of capsules, tablets, and pills, the dosage forms may also contain buffering agents. They may optionally contain opacifying agents, and they may be of a composition that releases the active ingredient only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of the embedding compositions that may be used include polymeric substances and waxes.

[0140] The dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed under sterile conditions with a pharma- ceutical acceptable carrier and, if necessary, with preservatives or buffers that are needed. Eye drop preparations, ear drops, and eye drops are also considered to be within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be prepared by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.

[0141] The amount of the compounds of the present invention that can be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host being treated, the particular mode of administration, etc. Preferably, the compositions provided should be formulated so that a dosage of 0.01-100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.

[0142] The compounds of the present invention may be administered alone or in combination with one or more other therapeutic compounds, where possible combination therapy takes the form of a fixed combination or where the administration of the compounds of the present invention and one or more other therapeutic compounds is alternating or administered independently of each other, or where the administration takes the form of a fixed combination in combination with one or more other therapeutic compounds. Examples of such other therapeutic agents include corticosteroids, rolipram, calphostin, cytokine suppressive anti-inflammatory drugs (CSAIDs), interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear transport inhibitors such as deoxyspergualin (DSG); nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib, and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, prograf); cytotoxic agents such as azathiprine and cyclophosphamide; TNF-α inhibitors such as tenizap, anti-TNF antibodies or soluble TNF receptors, and rapamycin (sirolimus or rapamune) or derivatives thereof. The compound of the present invention can be administered in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or combination thereof, especially for tumor therapy.As mentioned above, long-term therapy is equally possible, as well as adjuvant therapy in association with other therapeutic methods.Other possible treatments are therapy to maintain the condition of the patient after tumor regression, or even chemopreventive therapy, for example, in patients at risk.

[0143] These additional agents may be administered separately from the composition containing the compound of the present invention as part of a multiple dose treatment regimen. Alternatively, they may be part of a single dose form and mixed together with the compound of the present invention in a single composition. If administered as part of a multiple dose treatment regimen, the two active agents may be administered simultaneously, sequentially, or within a period of each other, usually within 5 hours of each other.

[0144] As used herein, the terms "combination," "in combination," and related terms refer to simultaneous or sequential administration of the therapeutic agents of the present invention. For example, a compound of the present invention may be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or together in a single unit dosage form. Thus, the present invention provides a single unit dosage form that includes a compound of the present invention, an additional therapeutic agent, and a pharma- ceutically acceptable carrier, adjuvant, or vehicle.

[0145] The amounts of both the compounds of the present invention and additional therapeutic agents that can be combined with the carrier materials to produce a single dosage form (in those compositions containing additional therapeutic agents as described above) will vary depending on the host treated and the particular route of administration. Preferably, the compositions of the present invention should be formulated so that the compound of the present invention can be administered at a dosage of between 0.01-100 mg / kg body weight / day.

[0146] In those compositions which include an additional therapeutic agent, the additional therapeutic agent and the compound of the invention may act synergistically, and thus, the amount of the additional therapeutic agent in such a composition will be less than the amount required in a monotherapy utilizing only that therapeutic agent.

[0147] The amount of additional therapeutic agent incorporated in the compositions of the invention will not exceed the amount that would normally be administered in a composition containing that therapeutic agent as the sole active agent. Preferably, the amount of additional therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount typically present in a composition containing that agent as the only therapeutically active agent.

[0148] It should also be recognized that the particular dosage and treatment regimen for a particular patient will depend on a variety of factors, including the activity of the particular compounds employed, age, body weight, general health, sex, diet, duration of administration, excretion rate, drug combination, as well as the judgment of the attending physician and the severity of the particular disease being treated. The amount of a compound of the invention in a composition will also depend on the particular compound in the composition. 5. Uses of the Compounds and Pharmaceutically Acceptable Compositions

[0149] The compounds and compositions described herein are generally useful for inhibiting PAD4.

[0150] The activity of the compound used in the present invention as an inhibitor of PAD4 can be assayed in vitro, in vivo or in cell line.In vitro assays include assays that measure the inhibition of PAD4.The detailed conditions for assaying the compound used in the present invention as an inhibitor of PAD4 are described in the following examples.In some embodiments, the compound provided selectively inhibits PAD4 compared to PAD2.

[0151] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of, a disease or disorder described herein, or one or more symptoms thereof. In some embodiments, treatment may be administered after onset of one or more symptoms. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals prior to onset of symptoms (e.g., taking into account a history of the condition and / or taking into account genetic or other susceptibility factors). Treatment may also be continued after resolution of symptoms, e.g., to prevent or delay their recurrence.

[0152] The compounds provided are inhibitors of PAD4 and are therefore useful for treating one or more disorders associated with the activity of PAD4. Thus, in certain embodiments, the present invention provides a method of treating a PAD4-mediated disorder, comprising administering to a patient in need thereof a compound of the present invention or a pharma- ceutical acceptable composition thereof.

[0153] In one embodiment, the PAD4-mediated disorder is a disease, condition or disorder mediated by inappropriate PAD4 activity.In some embodiments, the PAD4-mediated disorder is selected from the group consisting of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus and psoriasis.In a further embodiment, the disorder mediated by inappropriate PAD4 activity is rheumatoid arthritis.In a further embodiment, the disorder mediated by inappropriate PAD4 activity is systemic lupus erythematosus.In a further embodiment, the disorder mediated by inappropriate PAD4 activity is vasculitis.In a further embodiment, the disorder mediated by inappropriate PAD4 activity is cutaneous lupus erythematosus.In a further embodiment, the disorder mediated by inappropriate PAD4 activity is psoriasis.

[0154] In one embodiment, a method of treating rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis is provided, comprising administering to a human subject in need thereof a therapeutically effective amount of a provided compound, or a pharma- ceutical acceptable salt thereof.

[0155] In one embodiment, a method of treating rheumatoid arthritis is provided, comprising administering to a human subject in need thereof a therapeutically effective amount of a provided compound or a pharma- ceutically acceptable salt thereof. In one embodiment, a method of treating systemic lupus erythematosus is provided, comprising administering to a human subject in need thereof a therapeutically effective amount of a provided compound or a pharma- ceutically acceptable salt thereof. In one embodiment, a method of treating vasculitis is provided, comprising administering to a human subject in need thereof a therapeutically effective amount of a provided compound or a pharma- ceutically acceptable salt thereof. In one embodiment, a method of treating cutaneous lupus erythematosus or psoriasis is provided, comprising administering to a human subject in need thereof a therapeutically effective amount of a provided compound or a pharma- ceutically acceptable salt thereof. In one embodiment, a method of treating psoriasis is provided, comprising administering to a human subject in need thereof a therapeutically effective amount of a provided compound or a pharma- ceutical acceptable salt thereof.

[0156] In some embodiments, the PAD4 mediated disorder is selected from the group consisting of acid induced lung injury, acne (PAPA), acute lymphocytic leukemia, acute respiratory distress syndrome, Addison's disease, adrenal hyperplasia, adrenal insufficiency, aging, AIDS, alcoholic hepatitis, alcoholic liver disease, allergen induced asthma, allergic bronchopulmonary, aspergillosis, allergic conjunctivitis, alopecia, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, and weight loss, angina, angioedema, anhidrotic ectodermal dysplasia with immunodeficiency, ankylosing spondylitis, anterior segment inflammation, antiphospholipid syndrome, aphthous stomatitis, and rheumatoid arthritis. Enditis, appendicitis, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoimmune pneumonia, bee sting-induced inflammation, Behçet's disease, Behçet's syndrome, Bell's palsy, beryllium poisoning, Blau's syndrome, bone pain, bronchitis, burns, pouchitis, cancer, cardiac hypertrophy, carpal tunnel syndrome, catabolic disorders, cataracts, cerebral aneurysms, chemical irritant-induced inflammation, chorioretinitis, chronic heart failure, chronic lung disease of prematurity, chronic lymphocytic leukemia, chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, connective tissue diseases, corneal ulcers, Crohn's disease, cryopreservation syndrome, cryptococcosis Disease, Cystic fibrosis, Deficiency of interleukin-1 receptor antagonist (DIRA), Dermatitis, Dermatitis endotoxemia, Dermatomyositis, Diffuse pontine glioma, Endometriosis, Endotoxemia, Epicondylitis, Erythroblastopenia, Familial amyloidotic polyneuropathy, Familial cold urticaria, Familial Mediterranean fever, Fetal growth retardation, Glaucoma, Glomerular disease, Glomerulonephritis, Gout, Gouty arthritis, Graft-versus-host disease, Intestinal disease, Head injury, Headache, Hearing loss, Heart disease, Hemolytic anemia, Henoch-Scholein purpura, Hepatitis, Hereditary periodic fever syndromes, Shingles and Herpes simplex, HIV-1, Hodgkin's disease, Hansen's disease Chinton's disease, hyaline membrane disease, hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D with recurrent fever (HIDS), hypoplastic and other anemias, aplastic anemia, idiopathic thrombocytopenic purpura, incontinentia pigmenti, infectious mononucleosis, inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, iris, irritant-induced inflammation, ischemia / reperfusion, juvenile rheumatoid arthritis, keratitis, kidney disease, kidney damage caused by parasitic infection, kidney transplant rejection prevention, leptospirosis, leukemia, Löffler's syndrome, lung injury, lupus,Lupus nephritis, lymphoma, meningitis, mesothelioma, mixed connective tissue disease, McWell syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, gravitational myasthenia, cardiomyopathy, mycosis fungoides, myelodysplastic syndrome, myositis, rhinosinusitis, necrotizing enterocolitis, neonatal-onset multisystem inflammatory disease (NOMID), nephrotic syndrome, neuritis, neuropathological diseases, non-allergen-induced asthma, obesity, ocular allergy, optic neuritis, Organ transplants, osteoarthritis, otitis media, Paget's disease, pain, pancreatitis, Parkinson's disease, pemphigus, pericarditis, periodic fever, periodontitis, peritoneal endometriosis, whooping cough, pharyngitis and adenitis (PFAPA syndrome), plant irritant induced inflammation, pneumonia, pneumonitis, pneumonia infection, poison ivy / urushiol oil induced inflammation, polyarteritis nodosa, polychondritis, polycystic kidney disease, polymyositis, psoriasis, psychosocial stress disorders, lung disease, pulmonary hypertension, pulmonary fibrosis, ganglioside pyoderma , purulent aseptic arthritis, kidney disease, retinal disease, rheumatic carditis, rheumatic disease, rheumatoid arthritis, sarcoidosis, seborrhea, sepsis, severe pain, sickle cell, sickle cell anemia, silica-induced disease, Sjogren's syndrome, skin disease, sleep apnea, solid tumors, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid hemorrhage, sunburn, temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue transplantation, TNF receptor-associated cyclic inflammatory disease The disease is selected from the group consisting of: chronic obstructive pulmonary disease (COPD), chronic obstructive pulmonary disease (COPD), chronic pulmonary syndrome (COPS), toxoplasmosis, transplantation, traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticaria, uveitis, Wegener's granulomatosis, interstitial lung disease, psoriatic arthritis, juvenile idiopathic arthritis, Sjogren's syndrome, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, antiphospholipid syndrome, sepsis, deep vein thrombosis, fibrosis, Alzheimer's disease, scleroderma, and CREST syndrome.

[0157] In one embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in therapy. In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in the treatment of disorders mediated by inappropriate PAD4 activity. In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis. In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis. In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in the treatment of systemic lupus erythematosus. In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in the treatment of vasculitis. In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, for use in the treatment of cutaneous lupus erythematosus. In another embodiment, the present invention provides a compound provided herein, or a pharma- ceutically acceptable salt thereof, for use in treating psoriasis. In another embodiment, the present invention provides a compound provided herein, or a pharma- ceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment, the present invention provides a compound provided herein, or a pharma- ceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis. In another embodiment, the present invention provides a compound provided herein, or a pharma- ceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of rheumatoid arthritis. In another embodiment, the present invention provides a compound provided herein, or a pharma- ceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of systemic lupus erythematosus.In another embodiment, the present invention provides the use of a provided compound, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of vasculitis. In another embodiment, the present invention provides the use of a provided compound, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cutaneous lupus erythematosus. In another embodiment, the present invention provides the use of a provided compound, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of psoriasis. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing a disorder mediated by inappropriate PAD4 activity, comprising a provided compound, or a pharma- ceutically acceptable salt thereof. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis, comprising a provided compound, or a pharma- ceutically acceptable salt thereof. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing rheumatoid arthritis, comprising a provided compound, or a pharma- cetically acceptable salt thereof. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing systemic lupus erythematosus, comprising a compound provided herein, or a pharma- ceutically acceptable salt thereof. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing vasculitis, comprising a compound provided herein, or a pharma- ceutically acceptable salt thereof. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing cutaneous lupus erythematosus, comprising a compound provided herein, or a pharma- ceutically acceptable salt thereof. In a further embodiment, the present invention provides a pharmaceutical composition for treating or preventing psoriasis, comprising a compound provided herein, or a pharma- ceutically acceptable salt thereof.

[0158] All features of each aspect of the invention apply mutatis mutandis to all other aspects.

[0159] In order that the invention described herein may be more fully understood, the same is illustrated by the following examples, which should be understood as being for illustrative purposes only and should not be construed as limiting the invention in any manner.

[0160] Materialization As described in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. Although the general methods are directed to the synthesis of specific compounds of the invention, it will be understood that the following general methods, and other methods known to those of skill in the art, can be applied to all compounds described herein, and to each of the sub-classes and species of these compounds.

[0161] Certain compounds of the present invention were prepared according to the following schemes. Scheme 1 [ka]

[0162] For compounds involving heteroatom coupling, see Scheme 2. Scheme 2 [ka]

[0163] For the synthesis of the sulfone, see Scheme 3. Scheme 3 [ka]

[0164] For the synthesis of carboxamides see Scheme 4. Scheme 4 [ka]

[0165] For the synthesis of compounds requiring photoredox reactions, see Scheme 5. Scheme 5 [ka]

[0166] Analytical LCMS method description:

[0167] Method 1: Column: Waters Xbridge C18, 2.1 mm x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0% B to 100% B over 3 min, then hold at 100% B for 0.5 min; Flow rate: 1 mL / min; Detection: MS and UV (220 nm).

[0168] Method 2: Column: Waters Xbridge C18, 2.1 mm x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 0% B to 100% B over 3 min, then hold at 100% B for 0.5 min; Flow rate: 1 mL / min; Detection: MS and UV (220 nm).

[0169] Method 3: Waters Acquity UPLC BEH C18, 2.1x50mm, 1.7μm particles; Mobile phase A: water + 0.05% TFA; Mobile phase B: ACN + 0.05% TFA; Gradient: 2-98% B over 1 min, then hold at 98% B for 0.5 min; Flow rate: 0.8mL / min; Detection: UV (254nm)

[0170] The structure shown generally in this application as A below (Figure 1) is meant to represent the completely chiral structure B, which has a chiral azabicycloheptane moiety designated ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl). Figure 1 [ka]

[0171] Intermediate 1 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid [ka]

[0172] Methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate (4 g, 9.41 mmol) [for this starting material see WO 2017 / 0100594] was dissolved in THF (45 mL), MeOH (15 mL) and 2M aqueous LiOH (9.41 mL). This was stirred at 70° C. for 90 min. In addition to this procedure, the reaction was repeated as follows: Methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate (2.9 g, 6.83 mmol) was dissolved in THF (24 mL), MeOH (8 mL) and 2M aqueous LiOH (6.83 ml). LCMS showed that the saponification was complete. This crude was combined with the previous reaction crude. The mixture was treated slowly with 2N HCl until the pH reached about 6. At this stage, a pale yellow solid precipitated as 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (6.9 g). 1H NMR (400MHz, DMSO-d6) δ 12.83(brs,1H), 8.20(d,J=8.3Hz,1H), 7.96(s,1H), 7.41(s,1H), 7.28(d,J=8.2Hz,1H), 7.17(s,1H), 4.44(brd, J=6.9Hz,2H), 4.15(s,3H), 4.02(s,3H), 1.18-1.04(m,1H), 0.36-0.27(m,2H), 0.13(q,J=4.7Hz,2H), LCMS(M+H) + = 411.3, hold time = 1.01 min (Method 3)

[0173] Intermediate 2 tert-Butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate [ka]

[0174] To a mixture of 5-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (5.8 g, 14.12 mmol), tert-butyl ((7R)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (3.30 g, 15.53 mmol), and Hunig's base (7.40 ml, 42.4 mmol) was added DMF (35 mL). The mixture became solid, so more DMF (100 ml) was added (became a slurry). This was then treated portionwise with HATU (6.44 g, 16.94 mmol) to dissolve the HATU before adding the next portion. The reaction proceeded to eventually become a yellow solution. After stirring at room temperature for 2 hours, the reaction was found to be complete. The reaction mixture was diluted with EtOAc and washed with 10% aqueous LiCl (2x) followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered and concentrated to a dark tan oil. The brown oil was purified by flash chromatography (EtOAc / Hexanes) and the product fractions were combined and concentrated to give tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (11 g): 1H NMR (400MHz, DMSO-d6) δ 8.19(d,J=8.2Hz,1H), 7.51-7.36(m,1H), 7.27(d,J=8.2Hz,1H), 7.13(s,1H), 7.01-6.95(m,1H) ), 4.44(brd,J=7.1Hz,2H), 4.12(s,3H), 4.00(s,3H), 3.74-3.45(m,2H), 3.32(s,1H), 3.11-3.0 3(m,1H), 2.48-2.37(m,1H), 2.00-1.89(m,1H), 1.80(brs,2H), 1.52-1.44(m,1H), 1.44-1.28(m ,9H), 1.15-1.05(m,J=4.6Hz,1H), 0.30(brd,J=7.7Hz,2H), 0.13(brd,J=4.8Hz,2H), LCMS(M+H) + = 605.3, retention time = 1.05 min (Method 3).

[0175] Intermediate 3 tert-Butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate [ka]

[0176] A portion (9 g) of the above tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate was dissolved in DCM (100 mL) and treated with TFA (25 mL). After 2 h, additional TFA (15 mL) was added. After 1 h, the reaction was concentrated and then it was dissolved in EtOAc. It was made basic by very slow addition of solid NaHCO3. After the bubbling subsided, it was allowed to stir for an additional 30 min. The organic layer was separated and washed with brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered and concentrated to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (7g): 1 H NMR (400MHz, DMSO-d6) δ 8.20(d,J=8.2Hz,1H), 7.55-7.39(m,1H), 7.28(d,J=8.2Hz,1H), 7.15(s,1H), 7.0 2-6.95(m,1H), 4.44(brd,J=6.9Hz,2H), 4.13(s,3H), 4.07-4.04(m,1H), 4.00(s,3) H), 3.79-3.40(m,2H), 3.19-3.10(m,1H), 2.48-2.43(m,1H), 1.97-1.81(m,3H), 1 .62-1.53(m,1H), 1.14-1.02(m,1H), 0.35-0.28(m,2H), 0.12(brs,2H);LCMS(M+H) + = 505.3, retention time = 0.86 min (Method 3) as a yellow foamy solid.

[0177] Example 1 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one [ka]

[0178] A 2-dram (2 dr) pressure vial was charged with ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (25 mg, 0.053 mmol), 6-(4,4,5,5-tetrahydrofuran-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl) ...pyrrolo[2,3-b]pyridin-2-yl)-1H-benzo[d]imidazol-5-yl)methanone (25 mg, 0.053 mmol), 6-(4,4,5,5-tetrahydrofuran-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrrolo[2,3-b]py tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one (17.25 mg, 0.063 mmol), 3M aqueous potassium phosphate tribasic (0.053 mL, 0.158 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (4.30 mg, 5.26 μmol). The vial was stoppered and the reaction mixture was made anaerobic by pumping / backfilling with nitrogen cycles (5x). The reaction was allowed to stir at 70° C. for 7 h. The mixture was concentrated under vacuum to dryness. It was dissolved in DMF and purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 200mm x 19mm, 5μm particles; Mobile phase A: 5:95 acetonitrile:water + 10mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10mM ammonium acetate; Gradient: 15% B hold for 0 min, 15-55% B over 20 min, then 100% B hold for 4 min; Flow rate: 20mL / min; Column temperature: 25°C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine and shaken for a minimum of 2 hours. The resulting mixture was filtered and dried via centrifugal evaporation to give 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one (12 mg): 1H NMR (500MHz, DMSO-d6) δ 10.08(s,1H), 8.15(d,J=8.2Hz,1H), 8.02-7.97(m,2H), 7.89-7.78(m,1H), 7.76-7.69(m,2H), 7.45(brd,J=8.6Hz,1H), 7.10 (s,1H), 7.01(d,J=8.2Hz,1H), 4.64(brd,J=7.0Hz,2H), 3.99(s,3H), 3.74(brs,1H), 3.63-3.48(m,1H), 3.35-3.27(m,1H), 3. 17-3.04(m,1H), 3.01(brt,J=7.5Hz,2H), 2.56-2.52(m,3H), 2.23(brs,1H), 2.06-1.91(m,2H), 1.72(brt,J=9.3Hz,1H), 1.4 9-1.39(m,1H), 1.23(brd,J=8.4Hz,1H), 0.32(brd,J=7.8Hz,2H), 0.23(brs,2H); LC / MS(M+H)=585.9; retention time=1.43 min (method 1) were obtained.

[0179] Example 2 ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((6-fluoropyridin-3-yl)oxy)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka]

[0180] A 1-dram vial was charged with tert-butyl ((1R,4R,7R)-2-(2-(6-bromo-1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (0.037 g, 0.040 mmol), 2-fluoro-5-hydroxypyridine (5.42 mg, 0.048 mmol), cesium carbonate (0.020 g, 0.060 mmol) and Rockphos Pd G3 (3.35 mg, 3.99 μmol) in dioxane (1 mL). The vial was stoppered and the reaction mixture was made anaerobic with pump-down / backfill with nitrogen cycles (5x). The reaction was allowed to stir at 90° C. overnight. After cooling, the mixture was diluted with EtOAc, dried (MgSO4), filtered and concentrated. The resulting residue was dissolved in dichloromethane (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). The mixture was allowed to stir at room temperature for 90 minutes after which it was concentrated. The residue was dissolved in DMF, filtered and purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 19×200 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 26-66% B over 20 minutes, then hold at 100% B for 4 minutes; Flow rate: 20 mL / min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine, and shaken for a minimum of 2 hours. The resulting mixture was filtered and concentrated via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((6-fluoropyridin-3-yl)oxy)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (4.1 mg): 1H NMR (500MHz, DMSO-d6) δ 8.03(brs,1H), 7.72(brd,J=8.5Hz,1H), 7.68(brt,J=6.0Hz,1H), 7.44(brs,1H), 7.34(s,1H), 7.21(brdd,J=8.7, 2.9H z,1H), 7.06(s,1H), 6.95-6.90(m,2H), 4.37(brd,J=6.4Hz,2H), 4.10(s,3H), 3.98(s,3H), 3.75(brs,1H), 3.66-3.48( m,1H), 3.17(s,1H), 3.08-2.99(m,1H), 2.21(brs,1H), 2.04-1.91(m,2H), 1.74(brt,J=9.5Hz,1H), 1.48-1.40(m,1H), 1.23(s,2H), 1.04-0.94(m,1H), 0.26(brd,J=7.9Hz,2H), -0.02(brs,2H); LC / MS(M+H)=581.3; retention time=1.75 min (method 1) were obtained.

[0181] Example 3 ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka]

[0182] tert-Butyl A mixture of ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (47 mg, 0.078 mmol), Pd2(dba)3 (14.22 mg, 0.016 mmol), (2R)-1-[(1R)-1-[bis(1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)ferrocene (8.61 mg, 0.016 mmol) in DME (1.5 mL) was treated with potassium tert-butoxide (10.46 mg, 0.093 mmol). The vial was sealed and the reaction mixture was made anaerobic by pumping / back-filling with nitrogen (5x). The reaction was allowed to stir at room temperature for 10 minutes. The vial was capped under nitrogen flush and treated with 4-mercaptopyridine (10.36 mg, 0.093 mmol). The vial was stoppered and made anaerobic by pumping / back-filling with nitrogen (3x). The reaction mixture was stirred at 110° C. overnight. The desired product was observed along with starting material by LCMS. The reaction was repeated to obtain additional product. Details are as follows: tert-Butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (110 mg, 0.182 mmol), (2R)-1-[(1R)- A mixture of 1-[bis(1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)ferrocene (20.16 mg, 0.036 mmol), Pd2(dba)3 (33.3 mg, 0.036 mmol) in dioxane (2 mL) was treated with potassium tert-butoxide (24.48 mg, 0.218 mmol) under nitrogen flush. The vial was sealed and the reaction mixture was made anaerobic by pumping / backfilling with nitrogen cycles (5x). The reaction was allowed to stir at room temperature for 10 min.The vial was uncapped under nitrogen flush and treated with 4-mercaptopyridine (24.25 mg, 0.218 mmol). The vial was stoppered and made anaerobic by pumping / backfilling with nitrogen (3x). The reaction mixture was stirred at 110°C for 20 h. After cooling, the reaction was quenched with saturated aqueous NH4Cl. It was diluted with EtOAc and then washed with water followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined and dried (MgSO4). The crude products from the two runs were combined and purified by flash chromatography (12 g ISCO cartridge with EtOAc-hexanes). The product fractions were combined and concentrated (crude weight = 0.1 g). The resulting residue was dissolved in DCM (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). After 1 h, the solution was concentrated and the residue was dissolved in DMF, filtered and purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 200mm x 19mm, 5μm particles; Mobile phase A: 5:95 acetonitrile:water + 10mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10mM ammonium acetate; Gradient: 24% B hold for 0 min, 24-64% B over 20 min, then 100% B hold for 4 min; Flow rate: 20mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (10.1 mg): 1H NMR (500MHz, DMSO-d6) δ 8.49(brs,2H), 8.21(brd,J=7.9Hz,1H), 7.41-7.35(m,4H), 7.15(s,1H), 6.98-6.93(m,1H), 4. 37(brd,J=6.1Hz,2H), 4.14(s,3H), 4.00(brs,3H), 3.71(brs,2H), 3.57-3.47(m,1H), 3.10(br d,J=11.0Hz,1H), 2.91(s,1H), 2.75(s,1H), 1.92(brs,4H), 1.48(brt,J=8.4Hz,1H), 1.08-1.0 0(m,1H), 0.27(brd,J=7.6Hz,2H), 0.00(brs,2H); LC / MS(M+H)=580.4; retention time=1.58 min (method 1) was obtained.

[0183] Example 4 ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylsulfonyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka]

[0184] A mixture of tert-butyl ((1R,4R,7R)-2-(2-(6-bromo-1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (120 mg, 0.185 mmol), (2R)-1-[(1R)-1-[bis(1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)ferrocene (20.52 mg, 0.037 mmol), Pd2(dba)3 (33.9 mg, 0.037 mmol) in dioxane (2 mL) was treated with potassium tert-butoxide (24.91 mg, 0.222 mmol) under a nitrogen flush. The vial was sealed and the reaction mixture was made anaerobic by pumping / backfilling with nitrogen (5x). The reaction was stirred at room temperature for 10 min. The vial was uncapped under nitrogen flush and treated with 4-mercaptopyridine (30.8 mg, 0.278 mmol). The vial was stoppered and made anaerobic by pumping / backfilling with nitrogen (3x). The reaction mixture was stirred at 110° C. overnight. The reaction was quenched with saturated aqueous NH4Cl. It was diluted with EtOAc and then washed with water followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered and concentrated. The resulting residue was purified by flash chromatography (EtOAc / Hexanes) to give tert-butyl ((1R,4R,7R)-2-(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (38 mg, 0.056 mmol, 30.3% yield) as a brownish oil, which was dissolved in acetone (1.5 mL) and treated with water (1.500 ml) followed by oxone (103 mg, 0.168 mmol). This was stirred overnight. The reaction was diluted with EtOAc and then washed with 1.5 M aqueous K2HPO4 followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered and concentrated.The resulting residue was dissolved in CHCl (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). After stirring for 1 h, the deprotection was found to be complete. It was briefly concentrated to dryness under vacuum. The residue was dissolved in DMF and purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: 12% B hold for 0 min, 12-52% B over 20 min, then 100% B hold for 4 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine, and shaken for a minimum of 2 hours. The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylsulfonyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (12.6 mg, 0.020 mmol, 10.8% yield): 1H NMR (500MHz, DMSO-d6) δ 8.80(brd,J=5.5Hz,2H), 8.38(brs,1H), 7.90(brd,J=5.2Hz,2H), 7.87(brd,J=8.5Hz,1H), 7.62(brd,J=8.5Hz,1H) , 7.35(s,1H), 7.49-7.34(m,1H), 7.15(s,1H), 6.96-6.88(m,1H), 4.48(brd,J=7.0Hz,2H), 4.02(s,3H), 3.93(brs, 3H), 3.74-3.50(m,1H), 3.44-3.39(m,1H), 3.15-3.07(m,1H), 2.61(brs,1H), 1.96-1.77(m,3H), 1.65-1.52(m,1H) , 1.01-0.94(m,J=5.8Hz,1H), 0.26(brd,J=7.6Hz,2H), 0.00(brs,2H); LC / MS(M+H)=611.37; retention time=1.45 min (method 1).

[0185] Example 5 ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((4-hydroxyphenyl)amino)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka]

[0186] A vial was charged with tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (25 mg, 0.041 mmol), 4-aminophenol (6.76 mg, 0.062 mmol), cesium carbonate (40.4 mg, 0.124 mmol) and X-Phos precatalyst 2 (3.25 mg, 4.13 μmol) in dioxane (1 mL) and tBuOH (0.25 mL). The vial was stoppered and the reaction mixture was made anaerobic by pumping / backfilling with nitrogen (5x). The reaction was stirred at 70° C. overnight. After cooling, the mixture was diluted with EtOAc, dried (MgSO4), filtered, and concentrated. The resulting residue was dissolved in CH2Cl2 (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). The mixture was stirred at room temperature for 2 hours, after which it was concentrated. The resulting residue was dissolved in DMF and purified via preparative LC / MS under the following conditions: column: Xbridge C18, 200 mm x 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; gradient: 17% B hold for 0 minutes, 17-57% B over 20 minutes, then 100% B hold for 4 minutes; flow rate: 20 mL / min; column temperature: 25° C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine, and shaken for a minimum of 2 hours. The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((4-hydroxyphenyl)amino)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (13.8 mg, 0.024 mmol, 57.8% yield): 1H NMR (500MHz, DMSO-d6) δ 8.83(s,1H), 7.75(d,J=8.5Hz,1H), 7.56(brd,J=8.9Hz,2H), 7.40-7.27(m,1H), 6.89-6.79(m,2H), 6.68(brd, J=8.9Hz,2H), 6.59(d,J=8.5Hz,1H), 4.39(brd,J=6.7Hz,2H), 4.08(s,3H), 3.93(s,3H), 3.73(brs,1H), 3.65- 3.42(m,1H), 3.16-2.95(m,2H), 2.22-2.07(m,1H), 2.00-1.87(m,2H), 1.77-1.60(m,1H), 1.44-1.28(m,1H), 1 .11(brs,1H), 0.25(brd,J=7.9Hz,2H), 0.13(brd,J=4.0Hz,2H); LC / MS(M+H)=578.26; retention time=1.41 min (method 1) were obtained.

[0187] Intermediate 4 2-(5-((1R,4R,7R)-7-((tert-butoxycarbonyl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-carboxylic acid [ka]

[0188] tert-Butyl ((1R,4R,7R)-2-(2-(6-bromo-1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (0.36 g, 0.555 mmol), DPPF (0.062 g, 0.111 mmol) and TEA (0.232 mL, 1.665 mmol) in DMF (2 mL) and MeOH (0.500 mL) were bubbled with CO (gas) for 5 min, after which the reaction solution was treated with palladium(II) acetate (0.037 g, 0.056 mmol). CO (gas) was bubbled for an additional 1 min. The vial was sealed and a balloon containing carbon monoxide was connected to the vial via a needle, which was then stirred at 90°C.

[0189] After stirring overnight, the reaction was found to be complete. Additional amounts of DPPF (0.062 g, 0.111 mmol), MeOH (0.500 mL), and palladium(II) acetate (0.037 g, 0.056 mmol) were added to the reaction, and the solution was saturated by bubbling CO(g) for 5 min. The vial was sealed and a CO(g) balloon was attached. The mixture was stirred at 90° C. for another 18 h. After cooling, the mixture was diluted with EtOAc and filtered through Celite. The mixture was then washed with 10% LiCl(aq) (2×), followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered, and concentrated. The resulting residue was purified by flash chromatography (EtOAc / Hexanes) to give the methyl ester as a brown oil, which was then dissolved in THF (2 mL) and MeOH (0.5 mL). The solution was treated with 2M aqueous LiOH (0.555 mL, 1.110 mmol). The reaction was stirred at 70° C. for 2 h. The temperature was then raised to 80° C. After 1 h the reaction was still not complete and 2M aqueous LiOH (0.278 mL, 0.555 mmol) was added and stirring was continued at 80° C. After 7 h the saponification was complete. After cooling the mixture was diluted with EtOAc and 2M HCl was added (pH=5). The organic layer was separated and then washed with brine. It was dried (MgSO4), filtered and concentrated to give intermediate 2-(5-((1R,4R,7R)-7-((tert-butoxycarbonyl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-carboxylic acid. LC / MS (M+H) = 614.3; retention time = 0.87 min (Method 3).

[0190] Example 6 2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indole-6-carboxamide [ka]

[0191] A mixture of 2-(5-((1R,4R,7R)-7-((tert-butoxycarbonyl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-carboxylic acid (30 mg, 0.049 mmol, from above procedure), 4-aminopyridine (4.38 μl, 0.059 mmol) and Hunig's base (0.026 ml, 0.147 mmol) in DMF (1 mL) was treated with HATU (22.30 mg, 0.059 mmol) at room temperature. The reaction was stirred at room temperature overnight. The reaction mixture was then diluted with EtOAc and washed with 10% LiCl (aq) followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered and concentrated. The resulting residue was dissolved in CH2Cl2 (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). After stirring for 1 h, the reaction was evaporated. The residue was dissolved in DMF and purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 19x200 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 14-54% B over 20 min, then hold at 100% B for 4 min; Flow rate: 20 mL / min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give 2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indole-6-carboxamide (5.9 mg, 10.01 μmol, 20.47% yield).1 H NMR (500MHz, DMSO-d6) δ 8.45(brt,J=5.4Hz,1H), 8.16-8.13(m,1H), 7.71-7.67(m,1H), 7.65-7.60(m,1H), 7.44-7.31(m,1H), 7.02(s,1H), 6.95-6.88(m,1H), 4.41( brd,J=6.7Hz,2H), 4.13(brd,J=8.3Hz,1H), 4.06(s,3H), 3.95(s,3H), 3.78-3.66(m,3H), 3.61(q,J=7.7Hz,1H), 3.49(brdd,J=8.3, 5.4Hz,1 H), 3.34-3.22(m,1H), 3.04(brd,J=11.5Hz,1H), 2.52(brs,2H), 2.24-2.12(m,1H), 2.02-1.88(m,3H), 1.78-1.68(m,1H), 1.62(dq,J=12.9, 6.5Hz,1H), 1.42(brs,1H), 1.20(brs,1H), 1.06(brs,1H), 0.28(brd,J=7.8Hz,2H), 0.00(brs,2H);LC / MS(M+H)=590.36;Retention time=1.25 minutes (Method 3)

[0192] Example 7 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one [ka]

[0193] A 2-dram vial was charged with ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (125 mg, 0.248 mmol), 6-(4,4,5,5 A mixture of 1,3-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one (81 mg, 0.297 mmol), 3M aqueous potassium phosphate tribasic (0.248 mL, 0.743 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (20.21 mg, 0.025 mmol) was charged. The vial was stoppered and the reaction mixture was made anaerobic by pumping / backfilling with nitrogen (5x). The reaction was stirred at 70° C. overnight. After cooling, the mixture was concentrated in vacuo to dryness. It was dissolved in DMF and purified by preparative HPLC. Prep HPLC conditions: starting %B=20, final %B=70, gradient time=15 min, flow rate=30 ml / min, wavelength=254, solvent pair=MeCN-H20-TFA; solvent A=0.1% TFA in water; solvent B=0.1% TFA in MeCN; column 2=1: Luna 5μ C18 30x100mm AXIA Product eluted at 7.92 min. The desired fractions were combined and diluted with EtOAc, then washed with 1.5M K2HPO4 (aq) followed by brine. The aqueous layers were combined and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered and concentrated. The residue was dissolved in DCM-MeOH and treated with 25 mg of Py-resin. This was shaken for 2 more hours, after which it was filtered and concentrated.The residue was dissolved in a water-acetonitrile mixture, frozen, and lyophilized to give 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one (55 mg, 0.086 mmol, 34.6% yield) as a white fluffy solid. 1 H NMR (500MHz, DMSO-d6) δ 10.08(s,1H), 8.15(d,J=8.2Hz,1H), 8.02-7.97(m,2H), 7.89-7.78(m,1H), 7.76-7.69(m,2H), 7.45(brd,J=8.6Hz,1 H), 7.10(s,1H), 7.01(d,J=8.2Hz,1H), 4.64(brd,J=7.0Hz,2H), 3.99(s,3H), 3.74(brs,1H), 3.63-3.48(m,1H), 3.35 -3.27(m,1H), 3.17-3.04(m,1H), 3.01(brt,J=7.5Hz,2H), 2.56-2.52(m,3H), 2.23(brs,1H), 2.06-1.91(m,2H), 1.72 (brt,J=9.3Hz,1H), 1.49-1.39(m,1H), 1.23(brd,J=8.4Hz,1H), 0.32(brd,J=7.8Hz,2H), 0.23(brs,2H);LCMS=(M+H) + = 616.3; hold time = 0.7 min (Method 3)

[0194] Example 8 ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(oxetan-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka]

[0195] tert-Butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (30 mg, 0.050 mmol) was dissolved in dioxane (0.5 mL) followed by 3-bromooxetane (6.79 mg, 0.050 mmol), (Ir[DF(CF3)PP Y]2(DTBPY)PF6 (1.112 mg, 0.992 μmol), sodium carbonate (0.011 mL, 0.198 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (0.798 mg, 2.97 μmol), tris(trimethylsilyl)silane (0.023 mL, 0.074 mmol), nickel(II) chloride·ethylene glycol dimethyl ether complex (0.545 mg, 2.479 μmol) were added and purged with nitrogen. This was stirred overnight in front of a Kessel lamp while cooling the reaction vial with a fan. After cooling, EtOAc was added, filtered, and concentrated. The resulting residue was dissolved in DCM (1 mL) followed by the addition of T-FA (2 mL). After 30 min, the mixture was concentrated. The resulting residue was purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 200mm x 19mm, 5μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: 10% B hold for 0 min, 10-50% B over 20 min, then 100% B hold for 4 min; Flow rate: 20mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-pyridine, and shaken for a minimum of 2 hours.The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(oxetan-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (5.8 mg, 0.01 mmol, 22.2%): 1 H NMR (500MHz, DMSO-d6, rotamer) δ 8.07-8.00(m,1H), 7.44(m,0.33H), 7.36-7.31(m,0.71H), 7.14-7.08(m,1H), 7.03-6.99(m,1H), 6.95-6.85(m,1H) , 4.94-4.89(m,2H), 4.88-4.83(m,2H), 4.52-4.42(m,3H), 4.14(m,0.25H), 4.07(s,3H), 3.94(s,3H), 3.79-3.72(m ,0.53H), 3.52-3.38(m,1H), 3.18-3.11(m,0.49H), 3.07-2.95(m,1H), 2.22(m,0.76H), 2.14(m,0.41H), 1.99-1.78 (m,2H), 1.77-1.62(m,1H), 1.48-1.30(m,1H), 1.13-1.01(m,1H), 0.32-0.20(m,2H), 0.17-0.06(m,2H);LCMS(M+H) + = 527.4; retention time: 1.37 min (method 1).

[0196] The examples shown in the table below were prepared in the same manner as outlined for Examples 1-8 above.

[0197] Table 1 [Table 3] [Table 4] [Table 5] [Table 6]

Table 7

[0198]

Table 8

Table 9

Table 10

Table 11

Table 12

[0199] Table 2

Table 13

Table 14

Table 15

Table 16

Table 17

[0200]

Table 18

Table 19

Table 20

Table 21

Table 22

[0201]

Table 23

Table 24

Table 25

Table 26

Table 27

[0202] Table 3

Table 28

Table 29

Table 30

Table 31

Table 32

[0203]

Table 33

Table 34

Table 35

Table 36

Table 37

[0204]

Table 38

Table 39

Table 40

Table 41

Table 42

[0205]

Table 43

Table 44

[0206] Table 4

Table 45

Table 46

Table 47

Table 48

Table 49

[0207]

Table 50

Table 51

Table 52

Table 53

Table 54

[0208]

Table 55

Table 56

Table 57

Table 58

Table 59

Table 60

[0209] Table 5

Table 61

Table 62

Table 63

Table 64

Table 65

Table 66

[0210]

Table 67

Table 68

Table 69

Table 70

Table 71

[0211]

Table 72

Table 73

Table 74

Table 75

Table 76

[0212] Table 6

Table 77

Table 78

Table 79

Table 80

Table 81

Table 82

Table 83

Table 84

Table 85

Table 86

Table 87

Table 88

Table 89

Table 90

Table 91

Table 92

Table 93

[0213] Table 7

Table 94

Table 95

Table 96

Table 97

Table 98

Table 99

Table 100

Table 101

Table 102

Table 103

Table 104

Table 105

Table 106

Table 107

Table 108

Table 109

Table 110

[0214] Table 8

Table 111

Table 112

Table 113

Table 114

Table 115

Table 116

Table 117

Table 118

Table 119

Table 120

Table 121

Table 122

Table 123

Table 124

Table 125

Table 126

Table 127

[0215] Table 9

Table 128

Table 129

Table 130

Table 131

[0216] Table 10 [Table 132] [Table 133] [Table 134] [Table 135] [Table 136] [Table 137] [Table 138] [Table 139] [Table 140] [Table 141] [Table 142] [Table 143] [Table 144]

[0217] Further experimental details are provided below for Examples 445-448. Example 445 ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka] Step A: Methyl 2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate [ka] A mixture of methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate (890 mg, 2.095 mmol) [for this starting material see: WO 2017 / 0100594], 1-ethoxyvinyltri-n-butyltin (0.856 mL, 2.51 mmol), Xantphos (364 mg, 0.628 mmol) and Pd2(dba)3 (192 mg, 0.209 mmol) in degassed dioxane (10 mL) was stirred at 100° C. for 18 hours under nitrogen. The mixture was cooled to room temperature. A 1.0 M aqueous solution of HCl (2.095 mL, 2.095 mmol) was added and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc (15 mL) and washed with saturated aqueous sodium bicarbonate (2x15 mL). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was subjected to ISCO flash chromatography (silica gel / hexane-EtOAc 100:0 to 0:100 gradient) to give methyl 2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445A (850 mg, 1.769 mmol, 84% yield): LCMS (M+H) = 433.4, retention time = 1.06 min (Method 3) as a light brown solid. Step B: Methyl (E)-2-(1-(cyclopropylmethyl)-6-(1-(hydroxyimino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate [ka] A mixture of methyl 2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445A (400 mg, 0.925 mmol), hydroxylamine hydrochloride (70.7 mg, 1.017 mmol) in MeOH (12 mL) was stirred at 60° C. for 3 h (J. Med. Chem. 2015, 55, 3364). The mixture was concentrated. The mixture was diluted with EtOAc (15 mL) and washed with saturated aqueous sodium bicarbonate (2×15 mL). The organic layer was dried over sodium sulfate and concentrated to give crude methyl (E)-2-(1-(cyclopropylmethyl)-6-(1-(hydroxyimino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445B as an off-white solid: LCMS (M+H)=448.5, retention time=0.95 min (Method 3), which was used in the next step. Step C: Methyl 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate [ka] To a solution of methyl (E)-2-(1-(cyclopropylmethyl)-6-(1-(hydroxyimino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445B from above in DCM (5.0 mL) under nitrogen at -78°C in a capped syringe tube was added 70% HF-pyridine (1310 mg, 9.25 mmol) and the mixture was stirred at -78°C for 15 minutes. A solution of tert-butyl nitrite (286 mg, 2.77 mmol) in DCM (5.0 mL) was added dropwise to the solution and the reaction was stirred at -78°C for 30 minutes and at room temperature for 1 hour. The mixture was then added to sulfuric acid (1.0 mL) and ice water (200 g) and the mixture was stirred at room temperature for 30 minutes. The organic layer was collected and washed with saturated aqueous sodium bicarbonate (35 mL). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was subjected to ISCO flash chromatography (silica gel / hexane-EtOAc 100:0 to 50:50 gradient) to give methyl 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445C (92 mg, 0.192 mmol, 20.79% yield): 1 H NMR (499MHz, chloroform-d) δ 8.23(d,J=1.2Hz,1H), 8.09(d,J=8.1Hz,1H), 7.56(d,J=8.1Hz,1H), 7.52-7 .47(m,1H), 6.84(s,1H), 4.55(d,J=7.2Hz,2H), 4.18(s,3H), 4.09-4.06(m, 3H), 3.99(s,3H), 2.16(t,J=18.5Hz,3H), 1.22-1.12(m,1H), 0.39-0.31(m, 2H), 0.23-0.17(m,2H); LCMS (M+H) = 455.4, retention time = 1.09 min (Method 3) was obtained as a white solid. Step D: 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid [ka] A mixture of methyl 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445C (102 mg, 0.224 mmol) and 2.0 M aqueous lithium hydroxide (561 μl, 1.122 mmol) in 5.0 mL of THF was stirred at 50° C. for 18 hours. A 1.0 M aqueous solution of HCl (1.20 mL) was added and the mixture was concentrated. The mixture was extracted with EtOAc (2x15 mL) and the ethyl acetate layer was dried over sodium sulfate and concentrated to give crude 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid 445D (101 mg, 0.218 mmol, 97% yield): LCMS (M+H) = 441.4, retention time = 0.96 min (Method 3) as a white solid. Example 445: ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka] 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid 445D (20 mg, 0.045 mmol), tert-butyl ((3R,5R)-5-fluoropiperidin-3-yl)carbamate (9.91 mg, 0.045 mmol), BOP (22.09 mg, 0.050 mmol) and TEA (31.6 μl, 0.227 mmol) in DMF (1.0 mL) were stirred at room temperature for 2 hours. The mixture was diluted with EtOAc (5 mL) and washed with saturated aqueous sodium bicarbonate (2×5 mL). The organic layer was dried over sodium sulfate and concentrated to give crude tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate; LCMS (M+H) = 641.6, retention time = 1.00 min (Method 3), which was used in the next step. A mixture of tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate in DCM (1.0 mL) and TFA (1.0 mL) was stirred at room temperature for 30 minutes. The mixture was concentrated. The resulting residue was purified by preparative HPLC (Phenomenex, Luna 5 micron 30x250mm, flow rate = 30ml / min, gradient = 20% A to 100% B in 30min, A = HO / ACN / TFA (90:10:0.1), B = HO / ACN / TFA (10:90:0.1)). The pure product fraction was loaded onto a Strata-XC 33um cationic mixed-mode polymer cartridge (0.30g), the cartridge was washed with methanol (20ml) and the product was eluted with 0.5N NH3 in methanol (5.0mL). The NH3 eluate was concentrated and the pure product was lyophilized with ACN / HO (1:1, 10 mL) to give ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 445 (16.90 mg, 0.031 mmol, 67.5% yield): 1H NMR (499 MHz, methanol-d4) δ 8.22 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 8.2 Hz, 1H), 7.44 (s, 1H), 7.05 (s, 1H), 7.02-6.95 (m, 1H), 4.82-4.64 (m, 1H), 4.48 (d, J = 7.2 Hz, 2H), 4.06 (s, 7H), 3.43-3.35 (m, 2H), 3.26-3.06 (m, 1H), 3.0 1-2.53 (m, 1H), 2.45-2.28 (m, 1H), 2.12 (t, J=18.5 Hz, 3H), 1.72-1.50 (m, 1H), 1.05-0.97 (m, 1H), 0.38-0.30 (m, 2H), 0.14-0.04 (m, 2H); LCMS (M+H)=541.5, retention time=0.83 min (Method 3) as a white powder. Example 446 ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka] Step A: tert-Butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate [ka] tert-Butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate is prepared starting with tert-butyl ((3R,5R)-1-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate using the procedure of Example 445, Step A, to give tert-butyl Obtained ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 446A: LCMS (M+H) = 619.4, retention time = 0.89 min (Method 3). Example 446: ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka] tert-Butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 446A (20 mg, 0.032 mmol) in THF (1.0 mL) was added with 0.5 M cyclobutylmagnesium bromide solution (194 μl, 0.097 mmol) in 2-methyltetrahydrofuran, and the mixture was stirred at room temperature for 60 minutes. The mixture was added to 10% aqueous ammonium chloride solution (10 mL). The mixture was extracted with EtOAc (15 mL). The organic layer was dried over sodium sulfate and concentrated to give crude tert-butyl ((3R,5R)-1-(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate: LCMS (M+H) = 675.4, retention time = 0.94 min (Method 3), which was used in the next step. A mixture of tert-butyl ((3R,5R)-1-(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate in DCM (1.0 mL) and TFA (0.40 mL) was stirred at room temperature for 30 minutes. The mixture was concentrated. The resulting residue was purified by preparative HPLC (Phenomenex, Luna 5 micron 30x250 mm, flow rate = 30 ml / min, gradient = 20% A to 100% B in 30 min, A = H2O / ACN / TFA (90:10:0.1), B = H2O / ACN / TFA (10:90:0.1)). The pure product fraction was loaded onto a Strata-XC 33um cationic mixed-mode polymer cartridge (0.30 g), the cartridge was washed with methanol (20 ml), and the product was eluted with 0.5N NH3 in methanol (5.0 mL). The NH3 eluate was concentrated and the product was lyophilized with ACN / H2O (1:1, 5 mL) to give ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 446 (8.19 mg, 0.014 mmol, 41.9% yield): 1H NMR (499MHz, methanol-d4) δ 8.08(d,J=8.2Hz,1H), 7.41(d,J=8.3Hz,2H), 6.99-6.95(m,2H), 4.83-4.63(m,1H), 4.48(brs,2H) , 4.26-3.96(m,7H), 3.47-3.35(m,1H), 3.24-3.15(m,1H), 3.03-2.92(m,1H), 2.79-2.53(m,1H), 2 .46-2.14(m, 2H), 2.05-1.93(m, 2H), 1.88-1.75(m, 1H), 1.74-1.46(m, 7H), 1.03-0.91(m, 1H), 0.33(brd, J=8.1 Hz, 2H), 0.07(brd, J=4.1 Hz, 2H); LCMS (M+H)=575.4, retention time=0.91 min (Method 3) as a white solid. Example 447 ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka] Step A: tert-Butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate [ka] To a solution of tert-butyl ((3R,5R)-1-(2-(6-bromo-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate (85 mg, 0.130 mmol) [starting from ethyl 6-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate, but prepared in a similar manner to intermediate 2] in anhydrous ethyl ether (10 mL) and anhydrous THF (3.0 mL) at −78° C. under nitrogen, was added a 1.60 M solution of n-butyllithium in hexanes (203 μl, 0.324 mmol) and the mixture was stirred at −78° C. for 30 minutes. Then 1,3-difluoropropan-2-one (14.63 mg, 0.156 mmol) was added to the mixture at -78°C, and the mixture was stirred at -78°C for 10 min and at room temperature for 1 h. The mixture was diluted with EtOAc (15 mL) and washed with saturated aqueous sodium bicarbonate (2x15 mL). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was subjected to ISCO flash chromatography (silica gel / hexanes-5% MeOH / EtOAc 100:0 to 0:100 gradient) to give tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 447A (35 mg, 0.052 mmol, 40.2% yield): LCMS (M+H) = 671.5, retention time = 0.86 min (Method 3). Example 447: ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone [ka] A mixture of tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 447A (35 mg, 0.052 mmol, 40.2% yield) in DCM (1.0 mL) and TFA (1.0 mL) was stirred at room temperature for 30 min. The solution was concentrated and the resulting residue was purified by preparative HPLC (Phenomenex, Luna 5 micron 30x250mm, flow rate = 30ml / min, gradient = 20% A to 100% B in 30min, A = HO / ACN / TFA (90:10:0.1), B = HO / ACN / TFA (10:90:0.1)). The pure product fraction was loaded onto a Strata-XC 33um cationic mixed-mode polymer cartridge (0.30g), the cartridge was washed with methanol (20ml) and the product was eluted with 0.5N NH3 in methanol (5.0mL). The NH3 eluate of the product was concentrated and the product was lyophilized with ACN / HO (1:1, 5 mL) to give ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 447 (16.30 mg, 0.029 mmol, 22.03% yield): 1 H NMR (500MHz, DMSO-d6) δ 7.97(d,J=8.2Hz,1H), 7.36(d,J=8.2Hz,1H), 7.13(s,1H), 6.87(s,1H) , 6.66(s,1H), 4.92-4.48(m,6H), 4.44-4.17(m,3H), 4.01-3.62(m,6H) , 2.79-2.43(m,2H), 2.04-1.88(m,1H), 1.47-1.16(m,1H), 1.08-0.87(m,2H), 0.19--0.10(m,4H); LCMS(M+H)=571.3, retention time=1.39 min (method 2). Example 448 2-(4-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy)acetamide [ka] ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (1.5 g, 2.495 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bicyclo[2.2.1]heptan-2-yl A mixture of (1,3,2-dioxaborolane) (0.760 g, 2.99 mmol) and potassium acetate (0.612 g, 6.24 mmol) in dioxane (12 mL) was sonicated in a 2-dram vial and treated with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (0.102 g, 0.125 mmol) and the vial was stoppered. The reaction mixture was made anaerobic by pumping / backfilling with nitrogen cycles (5x). It was allowed to stir at 90 °C for 5 h and the starting material was found to be consumed. The reaction mixture was evaporated to dryness under vacuum. The resulting brown solid was used alternatively in the next step. A portion of this material (45 mg, 0.047 mmol), 2-(4-bromophenoxy)acetamide (13.08 mg, 0.057 mmol), 2N aqueous sodium carbonate (0.071 mL, 0.142 mmol), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (3.87 mg, 4.74 μmol) in DMF (1 mL) were added. The vial was stoppered and the reaction mixture was made anaerobic by pumping / backfilling with nitrogen cycles (5x). The reaction was stirred at 70° C. overnight. After cooling to room temperature, the solution was diluted with DMF, filtered and purified via preparative LC / MS under the following conditions: Column: Xbridge C18, 200mm x 19mm, 5μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: 11% B hold for 0 min, 11-51% B over 20 min, then 100% B hold for 4 min; Flow rate: 20mL / min; Column temperature: 25°C. Fraction collection was triggered by the product MS signal.Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified product was then diluted with DMF, treated with Si-pyridine resin, and shaken for a minimum of 2 hours. The resulting mixture was filtered and dried via centrifugal evaporation to give 2-(4-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy)acetamide 448 (20.6 mg): 1 H NMR (500MHz, DMSO-d6) δ 8.17-8.13(m,3H), 7.95-7.92(m,1H), 7.78-7.74(m,1H), 7.62-7.53(m,2H), 7.44-7.40(m,1H), 7.11-7.08(m,2H), 7.08-7.06(m,1H), 7.02-6.94(m,1H), 4.57-4.52(m,2H), 4.52-4.50(m,2H), 4.18-4.12(m,3H), 4.03-3.95(m,3H), 3.83-3.71(m,1H), 3.66-3.54(m,1H), 3.53-3.44(m,1H), 3.22-3.15(m,1H), 2.69-2.57(m,1H), 2.02-1.85(m,3H), 1.74-1.59 (m, 1H), 1.28-1.11 (m, 2H), 0.35-0.29 (m, 2H), 0.20 (brs, 2H); LCMS (M+H) = 620.0, retention time = 1.58 min (method 1) were obtained.

[0218] The following compounds were synthesized using the above method.

[0219] [Table 145] [Table 146] [Table 147] [Table 148]

Table 149

[0220]

Table 150

Table 151

Table 152

Table 153

Table 154

[0221]

Table 155

Table 156

Table 157

Table 158

Table 159

[0222]

Table 160

Table 161

Table 162

Table 163

Table 164

[0223]

Table 165

Table 166

Table 167

Table 168

Table 169

[0224]

Table 170

Table 171

Table 172

Table 173

Table 174

[0225]

Table 175

Table 176

Table 177

Table 178

Table 179

[0226]

Table 180

Table 181

Table 182

Table 183

Table 184

[0227]

Table 185

Table 186

Table 187

Table 188

Table 189

[0228]

Table 190

Table 191

Table 192

Table 193

Table 194

[0229]

Table 195

Table 196

Table 197

Table 198

Table 199

[0230]

Table 200

Table 201

Table 202

Table 203

Table 204

[0231]

Table 205

Table 206

Table 207

Table 208

Table 209

[0232]

Table 210

Table 211

Table 212

Table 213

Table 214

[0233]

Table 215

Table 216

Table 217

Table 218

Table 219

[0234]

Table 220

Table 221

Table 222

Table 223

Table 224

[0235]

Table 225

Table 226

Table 227

Table 228

Table 229

[0236]

Table 230

Table 231

Table 232

Table 233

Table 234

[0237]

Table 235

Table 236

Table 237

Table 238

Table 239

[0238]

Table 240

Table 241

Table 242

Table 243

Table 244

[0239]

Table 245

Table 246

Table 247

Table 248

Table 249

[0240]

Table 250

Table 251

Table 252

Table 253

Table 254

[0241]

Table 255

Table 256

Table 257

Table 258

Table 259

[0242]

Table 260

Table 261

Table 262

Table 263

Table 264

[0243]

Table 265

Table 266

Table 267

Table 268

Table 269

[0244]

Table 270

Table 271

Table 272

Table 273

Table 274

[0245]

Table 275

Table 276

Table 277

Table 278

Table 279

[0246]

Table 280

Table 281

Table 282

Table 283

Table 284

[0247]

Table 285

Table 286

Table 287

Table 288

Table 289

[0248]

Table 290

Table 291

Table 292

Table 293

Table 294

[0249]

Table 295

Table 296

Table 297

Table 298

Table 299

[0250]

Table 300

Table 301

Table 302

Table 303

Table 304

[0251]

Table 305

Table 306

Table 307

Table 308

Table 309

[0252]

Table 310

Table 311

Table 312

Table 313

Table 314

[0253]

Table 315

Table 316

Table 317

Table 318

Table 319

[0254]

Table 320

Table 321

Table 322

Table 323

Table 324

[0255]

Table 325

Table 326

Table 327

Table 328

Table 329

[0256]

Table 330

Table 331

Table 332

Table 333

Table 334

[0257]

Table 335

Table 336

Table 337

Table 338

Table 339

[0258]

Table 340

Table 341

Table 342

Table 343

Table 344

[0259]

Table 345

Table 346

Table 347

Table 348

Table 349

[0260]

Table 350

Table 351

Table 352

Table 353

Table 354

[0261]

Table 355

Table 356

Table 357

Table 358

Table 359

[0262] Table 360

Table 361

Table 362

Table 363

Table 364

[0263]

Table 365

Table 366

Table 367

Table 368

Table 369

[0264]

Table 370

Table 371

Table 372

Table 373

Table 374

[0265]

Table 375

Table 376

Table 377

Table 378

Table 379

[0266]

Table 380

Table 381

Table 382

Table 383

Table 384

[0267]

Table 385

Table 386

Table 387

Table 388

Table 389

[0268]

Table 390

Table 391

Table 392

Table 393

Table 394

[0269]

Table 395

Table 396

Table 397

Table 398

Table 399

[0270]

Table 400

Table 401

Table 402

Table 403

Table 404

[0271]

Table 405

Table 406

Table 407

Table 408

Table 409

[0272]

Table 410

Table 411

Table 412

Table 413

Table 414

[0273]

Table 415

Table 416

Table 417

Table 418

Table 419

[0274] Table 420

Table 421

Table 422

Table 423

Table 424

[0275]

Table 425

Table 426

Table 427

Table 428

Table 429

[0276]

Table 430

Table 431

Table 432

Table 433

Table 434

[0277]

Table 435

Table 436

Table 437

Table 438

Table 439

[0278]

Table 440

Table 441

Table 442

Table 443

Table 444

[0279]

Table 445

Table 446

Table 447

Table 448

Table 449

[0280] Table 450

Table 451

Table 452

Table 453

Table 454

[0281]

Table 455

Table 456

Table 457

Table 458

Table 459

[0282]

Table 460

Table 461

Table 462

Table 463

Table 464

[0283]

Table 465

Table 466

Table 467

[0284] Biological assays The compounds of the present invention were assayed as inhibitors of PAD4 using the assay protocol described below.

[0285] RFMS Human PAD4 Functional Assay: Compounds were solubilized in 100% DMSO to a compound concentration of 10 mM. Compound stock solutions were stored at room temperature. Serial dilutions were prepared in DMSO and mixed 8 times with a mixing volume of 20 μL. The final top concentration of compound in the assay is 50 μM. Final assay conditions were as follows: Reaction volume: 26 μl Assay buffer: 25 mM Hepes, pH 7.5, 5 mM NaCl, 1 mM DTT, 0.2 mg / ml BSA, 0.01% CHAPS, 50 μM calcium, and 5 μM TPEN Final concentrations: 5 nM hPAD4 enzyme, 250 μM BAEE, and 0.5% DMSO Total incubation times: 30 min compound and enzyme preincubation at 37° C., 90 min enzyme / substrate reaction at 37° C., and 30 min reaction with phenylglyoxal. Stop solution: 40 μl 5% TCA in ACN It was.

[0286] A solution of compound (0.13 μL) was added to 10 nM PAD4 (13 μL) in assay buffer. After 30 min, 500 μM BAEE (13 μl) was added in 25 mM hepes, pH 7.5, 5 mM NaCl, 1 mM DTT, 0.2 mg / ml BSA, 0.01% CHAPS, 50 μM calcium, 5 μM TPEN, and the reaction was incubated at 37° C. for 90 min. 6.1 N TCA (15 μl) was added to quench the enzyme reaction, 100% Final Concentration is 20%, then 35 μl of 8.5 mM phenylglyoxal (final concentration 4 mM) was added, and the reaction was incubated at 37° C. for 30 min.

[0287] After 30 minutes, the plate is spun down to remove any precipitate. The enzyme reaction is quenched with an equal volume of methanol containing the internal standard (modified citrulline). The samples are loaded into a Rapid Fire RF300 system (Agilent), where they are first soaked for 1000 ms, then loaded directly onto a C18 separation cartridge using a mixture of acetonitrile containing 0.01% formic acid for 3000 ms to desalt. The flow rate of the mobile phase is 1.5 ml / min. Once the sample is eluted from the cartridge, it is transferred to the mass analyzer at a flow rate of 1.25 ml / min for 4000 ms using a mobile phase of acetonitrile containing 0.01% formic acid. Peptidyl citrulline and internal standard ions are analyzed using a Sciex API5500 triple quadrupole mass spectrometer (Applied Biosystems) equipped with ESI.

[0288] MRM transitions of the product and internal standard were monitored at m / z 424.5–350.4 and m / z 293–247, respectively. The dwell time for each transition was set at 200 ms, and the ESI voltage was used at 5500 with a source temperature of 400 °C. The extracted ion peaks for each transition were integrated using Rapid Fire Integrator software. Analyte peak areas were normalized using the internal standard.

[0289] For certain example compounds, the table below shows the IC for human PAD4 (hPAD4) in a rapid-fire mass spectrometry (RFMS) assay. 50 Shows.

[0290] Table 11. PAD4 activity [Table 470] [Table 471] [Table 472] [Table 473] [Table 474]

[0291] [Table 475] [Table 476] [Table 477] [Table 478] [Table 479]

[0292] [Table 480] [Table 481] [Table 482] [Table 483]

Table 484

[0293]

Table 485

Table 486

Table 487

Table 488

Table 489

[0294]

Table 490

Table 491

Table 492

Table 493

Table 494

[0295]

Table 495

Table 496

Table 497

Claims

1. Formula (I): 【Chemical 1】 [In the formula: Q is selected from N and CH; Ring A is 1 to 4 R ７ 4- to 15-membered heterocyclyl substituted by R １ is CH ３ , CDs ３ , and -CH ２ - 5-membered heterocyclyl (wherein the heterocyclyl is a carbon atom and N, NC １－４ and 1 to 3 heteroatoms selected from alkyl, O, and S; R ２ is H, 0 to 5 R ｅ C substituted with １－３ Alkyl, and -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ cycloalkyl; R ３ is H, F, Cl, Br, -OR ｂ , and 0 to 5 R ｅ C substituted with １－３ alkyl; L is absent or -NR ｄ -, -O-, -C(=O)NR ｄ -, and -S(O) ｐ - selected from; R ４ is -(CH ２ ) ｒ - 1 to 5 R ５ C substituted with ６ Aryl, -(CH ２ ) ｒ - a bicyclic heterocyclyl substituted with 1 to 7 R 5 , wherein the bicyclic heterocyclyl contains carbon atoms and 1 to 3 heteroatoms selected from N, NR 6 , O, and S, or -(CH ２ ) ｒ - monocyclic heteroaryl substituted with 1 to 7 R 5 , wherein said monocyclic heteroaryl contains carbon atoms and 1 to 3 heteroatoms selected from N, NR 6 , O, and S; R ５ are each H, F, Cl, Br, CN, ═O, nitro, 0 to 5 R ｅ C substituted with １－４ alkyl, 0 to 5 R ｅ C substituted with ２－４ alkenyl, 0 to 5 R ｅ C substituted with ２－４ Alkynyl, -(CHR ｄ ) ｒ OR ｂ , -(CHR ｄ ) ｒ S (O) ｐ R ｃ , -(CHR ｄ ) ｒ S (O) ｐ NR ａ R ａ , -(CHR ｄ ) ｒ NR ａ S (O) ｐ R ｃ , -(CHR ｄ ) ｒ NR ａ R ａ , -(CHR ｄ ) ｒ NR ａ C(=O)R ｂ , -(CHR ｄ ) ｒ NR ａ C(=O)OR ｂ , -(CHR ｄ ) ｒ NR ａ C(=O)NR ａ R ａ , -(CHR ｄ ) ｒ C(=O)R ｂ , -(CHR ｄ ) ｒ C(=O)OR ｂ , -(CHR ｄ ) ｒ C(=O)NR ａ R ａ , -(CHR ｄ ) ｒ OC(=O)R ｂ , -(CHR ｄ ) ｒ OC(=O)OR ｂ , -(CHR ｄ ) ｒ O (CH ２ ) ｒ C(=O)NR ａ R ａ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ６ is H, 0 to 4 R ｅ C substituted with １－３ Alkyl, —S(O) ｐ R ｃ , -(CH ２ ) ｒ C(=O)R ｂ , -(CH ２ ) ｒ -C(=O)OR ｂ , -(CH ２ ) ｒ C(=O)(CH ２ ) ｒ NR ａ R ａ , -C(=O)(CH ２ ) ｒ NR ａ C(=O)R ｂ , -S(O) ｐ NR ａ R ａ , -(CH ２ ) ｒ -0 to 4 R ｅ C substituted with ３－６ Cycloalkyl, -(CH ２ ) ｒ -0 to 4 R ｅ aryl substituted with -(CH ２ ) ｒ -0 to 4 R ｅ heterocyclyl substituted with; R ７ are H, F, Cl, CN, C １－３ Alkyl, =N-OR ｂ , -(CH ２ ) ｒ OR ｂ , -(CH ２ ) ｒ NR ａ R ａ , -NR ａ C(=NH)C １－３ Alkyl, —NR ａ C(=O)OR ｂ , carbocyclyl, and heterocyclyl; alternatively, two R ７ the groups taken together form a carbocyclyl or heterocyclyl; R ８ are each H, F, Cl, Br, and 0 to 5 R ｅ C substituted with １－４ independently selected from alkyl; R ａ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ or R ａ and R ａ and the nitrogen atom to which both of these are bonded and together form 0 to 5 R ｅ forming a heterocyclic ring substituted with R ｂ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of the R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｄ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, and OH; R ｅ Each of the R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, -(CH ２ ) ｒ -heterocyclyl, Si(C １－４ alkyl) ３ , F, Cl, Br, CN, NO ２ , =O, CO ２ H, -(CH ２ ) ｒ OR ｆ , S(O) ｐ R ｆ , C(═O)NR ｆ R ｆ , S(O) ｐ NR ｆ R ｆ , and -(CH ２ ) ｒ NR ｆ R ｆ more independently selected; R ｆ are each optionally substituted with H, F, Cl, Br, CN, OH, or OH; １－５ Alkyl, C ２－５ Alkenyl, C ２－５ Alkynyl, C ３－６ cycloalkyl, and phenyl, or R ｆ and R ｆ together with the nitrogen atom to which they are attached form C １－４ forming a heterocyclic ring optionally substituted with alkyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3, and 4; or a pharmaceutically acceptable salt thereof. 【Request 2】 【Chemical 2】 but 【Chemistry 3】 Selected from: R １ But CH ３ and CDs ３ Selected from: R ２ is methyl, ethyl and -CH ２ -0 to 3 R ｅ cyclopropyl substituted with; R ３ is H, F, Cl, Br, and -OC １－４ alkyl; L is absent or -NR ｄ -, -O-, -C(=O)NH-, -S-, and -S(O) ２ - selected from; R ４ teeth, 【Chemistry 4】 【Chemistry 5】 【Chemistry 6】 【Chemistry 7】 Selected from: R ５ are each H, F, Cl, Br, CN, ═O, 0 to 5 R ｅ C substituted with １－４ Alkyl, C ２－４ Alkenyl, C ２－４ Alkynyl, -(CHR ｄ ) ｒ OR ｂ , -(CH ２ ) ｒ S (O) ｐ R ｃ , -(CH ２ ) ｒ S (O) ｐ NR ａ R ａ , -(CH ２ ) ｒ NR ａ S (O) ｐ R ｃ , -(CH ２ ) ｒ NR ａ R ａ , -(CH ２ ) ｒ NR ａ C(=O)R ｂ , -(CH ２ ) ｒ NR ａ C(=O)OR ｂ , -(CH ２ ) ｒ NR ａ C(=O)NR ａ R ａ , -(CH ２ ) ｒ C(=O)R ｂ , -(CH ２ ) ｒ C(=O)OR ｂ , -(CHR ｄ ) ｒ C(=O)NR ａ R ａ , -(CH ２ ) ｒ OC(=O)R ｂ , -(CH ２ ) ｒ OC(=O)OR ｂ , -(CH ２ ) ｒ O (CH ２ ) ｒ C(=O)NR ａ R ａ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ６ are each H and 0 to 4 R ｅ C substituted with １－３ Alkyl, —S(O) ｐ R ｃ , -C(=O)R ｂ , -(CH ２ ) ｒ C(=O)OR ｂ , -(CH ２ ) ｒ C(=O)(CH ２ ) ｒ NR ａ R ａ , -C(=O)(CH ２ ) ｒ NR ａ C(=O)R ｂ , -S(O) ｐ NR ａ R ａ , -(CH ２ ) ｒ -0 to 4 R ｅ aryl substituted with -(CH ２ ) ｒ -0 to 4 R ｅ heterocyclyl substituted with R ａ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ or R ａ and R ａ and the nitrogen atom to which both of these are bonded and together form 0 to 5 R ｅ forming a heterocyclic ring substituted with R ｂ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of the R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｄ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, and OH; R ｅ Each of the R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, -(CH ２ ) ｒ -heterocyclyl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -(CH ２ ) ｒ OH, and -(CH ２ ) ｒ O.C. １－４ independently selected from alkyl; R ｆ are each optionally substituted with H, F, Cl, Br, CN, OH, or OH; １－５ Alkyl, C ３－６ independently selected from cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3 and 4; 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. Formula (II): 【Chemistry 8】 [In the formula: Q is selected from N and CH; 【Chemistry 9】 teeth 【Chemistry 10】 Selected from: R ２ is CH ３ , C.H. ２ CH ３ , and -CH ２ - 0 to 2 F, Cl and CH ３ cyclopropyl substituted with; R ３ is H, F, OH, and -OC １－４ alkyl; R ４ teeth, 【Chemistry 11】 【Chemistry 12】 Selected from: R ５ are each H, F, Cl, Br, CN, ═O, 0 to 4 R ｅ C substituted with １－４ Alkyl, -(CHR ｄ ) ｒ OR ｂ , -(CH ２ ) ｒ -S(O) ｐ R ｃ , -S(O) ｐ NR ａ R ａ , -(CH ２ ) ｒ NR ａ S (O) ｐ R ｃ , -(CH ２ ) ｒ NR ａ R ａ , -(CH ２ ) ｒ NR ａ C(=O)R ｂ , -NR ａ C(=O)OR ｂ , -NR ａ C(=O)NR ａ R ａ , -(CH ２ ) ｒ C(=O)R ｂ , -(CH ２ ) ｒ C(=O)OR ｂ , -(CHR ｄ ) ｒ C(=O)NR ａ R ａ , -(CH ２ ) ｒ OC(=O)R ｂ , -(CH ２ ) ｒ OC(=O)OR ｂ , -(CH ２ ) ｒ O (CH ２ ) ｒ C(=O)NR ａ R ａ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ６ are each H and 0 to 4 R ｅ C substituted with １－３ Alkyl, —S(O) ｐ R ｃ , -C(=O)R ｂ , -(CH ２ ) ｒ C(=O)OR ｂ , -(CH ２ ) ｒ C(=O)NR ａ R ａ , -C(=O)(CH ２ ) ｒ NR ａ C(=O)R ｂ , -S(O) ｐ NR ａ R ａ , 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ａ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ or R ａ and R ａ and the nitrogen atom to which both of these are bonded and together form 0 to 5 R ｅ forming a heterocyclic ring substituted with R ｂ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ Alkenyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of the R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｄ are each H and 0 to 5 R ｅ C substituted with １－６ independently selected from alkyl, and —OH; R ｅ Each of the R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, -(CH ２ ) ｒ -heterocyclyl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -C(=O)OC １－４ Alkyl, -(CH ２ ) ｒ OH, -(CH ２ ) ｒ O.C. １－４ Alkyl, and S(O) ２ C １－４ independently selected from alkyl; R ｆ are each optionally substituted with H, F, Cl, Br, CN, OH, or OH; １－５ Alkyl, C ３－６ independently selected from cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3, and 4; or a pharmaceutically acceptable salt thereof.

4. Formula (III): 【change】 [In the formula: 【Chemistry 13】 teeth 【Chemistry 14】 Selected from: R ２ Ha-CH ２ -cyclopropyl; R ３ Ha-OC １－４ is alkyl; R ５ are each H, F, Cl, Br, CN, 0 to 4 R ｅ C substituted with １－４ Alkyl, -(CHR ｄ ) ｒ OR ｂ , -(CH ２ ) ｒ S (O) ｐ R ｃ , -S(O) ｐ NR ａ R ａ , -(CH ２ ) ｒ NHS (O) ｐ R ｃ , -(CH ２ ) ｒ NR ａ R ａ , -(CH ２ ) ｒ NHC(=O)R ｂ , -NHC(=O)OR ｂ , -(CHR ｄ ) ｒ C(=O)NR ａ R ａ , -(CH ２ ) ｒ C(=O)OR ｂ , -OC(=O)OR ｂ , -O(CH ２ ) ０－１ C(=O)NR ａ R ａ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ａ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ or R ａ and R ａ and the nitrogen atom to which both of these are bonded and together form 0 to 5 R ｅ forming a heterocyclic ring substituted with R ｂ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ Alkenyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of the R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｄ are H and C, respectively. １－４ alkyl, and OH; R ｅ Each of the R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, -(CH ２ ) ｒ -heterocyclyl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -C(=O)OC １－４ Alkyl, -(CH ２ ) ｒ OH, -(CH ２ ) ｒ O.C. １－４ Alkyl, and SO ２ C １－４ independently selected from alkyl; R ｆ are each optionally substituted with H, F, Cl, Br, CN, OH, or OH; １－５ Alkyl, C ３－６ independently selected from cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3, and 4; 4. The compound according to claim 3, which is represented by the formula: or a pharmaceutically acceptable salt thereof.

5. R ３ Ga-OCH ３ and R ５ are H, F, Cl, Br, CN, and C, respectively. １－４ Alkyl, -(CH ２ ) ０－１ OR ｂ , -S(O) ２ NH ２ , -NHS(O) ２ C １－３ Alkyl, -NHS(O) ２ C ２－４ Alkenyl, —NHC(═O)R ｂ , —C(═O)NH ２ , and 【Chemistry 15】 independently selected from heterocyclyl selected from: R ｂ are each H and 0 to 5 R ｅ C substituted with １－６ independently selected from alkyl; R ｅ are respectively C １－６ Alkyl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -C(=O)OC １－４ Alkyl, -(CH ２ ) ｒ OH, -(CH ２ ) ｒ O.C. １－４ Alkyl, and SO ２ C １－４ alkyl; and each r is independently selected from 0 and 1; 5. The compound of claim 4 or a pharmaceutically acceptable salt thereof. 【Request 6】 【Chemical 16】 but 【Chemistry 17】 Selected from: R ２ Ha-CH ２ -cyclopropyl; R ３ Ga-OC １－４ is alkyl; R ４ but, 【Chemistry 18】 Selected from: R ５ are each H, F, Cl, Br, CN, 0 to 4 R ｅ C substituted with １－４ Alkyl, -(CH ２ ) ｒ OR ｂ , -S(O) ｐ R ｃ , -S(O) ｐ NR ａ R ａ , -(CH ２ ) ｒ NR ａ S (O) ｐ R ｃ , -(CH ２ ) ｒ NR ａ R ａ , -(CH ２ ) ｒ NR ａ C(=O)R ｂ , -NR ａ C(=O)OR ｂ , -NR ａ C(=O)NR ａ R ａ , -(CH ２ ) ｒ C(=O)R ｂ , -(CH ２ ) ｒ C(=O)OR ｂ , -(CH ２ ) ｒ C(=O)NR ａ R ａ , -(CH ２ ) ｒ OC(=O)R ｂ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ａ are H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ or R ａ and R ａ and the nitrogen atom to which both of these are bonded and together form 0 to 5 R ｅ forming a heterocyclic ring substituted with R ｂ are H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ Alkenyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of these has 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｅ Each of these has 0 to 5 R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -C(=O)OC １－４ Alkyl, -(CH ２ ) ｒ OH, -(CH ２ ) ｒ O.C. １－４ Alkyl, and S(O) ２ C １－４ independently selected from alkyl; R ｆ each optionally substituted with H, F, Cl, Br, CN, OH, OH １－５ Alkyl, C ３－６ independently selected from cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3 and 4; 4. The compound of claim 3 or a pharmaceutically acceptable salt thereof.

7. R ３ Ga-OCH ３ and R ５ are H, F, Cl, Br, and C, respectively. １－４ Alkyl, —OH, —OC １－３ Alkyl, -NHS(O) ２ C ２－４ Alkenyl, NHC(=O)OC １－４ Alkyl, C(=O)NH ２ , C(═O)NHC １－４ alkyl, and 【Chemistry 19】 and R ｅ However, each １－６ Alkyl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -C(=O)OC １－４ Alkyl, -(CH ２ ) ｒ OH, -(CH ２ ) ｒ O.C. １－４ Alkyl, and SO ２ C １－４ independently selected from alkyl, 7. The compound of claim 6 or a pharmaceutically acceptable salt thereof. 【Request 8】 【Chemical 20】 but 【Chemical 21】 Selected from: R ２ Ga-CH ２ -cyclopropyl; R ３ Ga-OC １－４ is alkyl; R ４ but, 【Chemical 22】 【Chemical 23】 Selected from: R ５ are H, F, Cl, Br, CN, and C, respectively. １－４ Alkyl, -OR ｂ , -S(O) ｐ R ｃ , -(CH ２ ) ｒ NR ａ S (O) ｐ R ｃ , -(CH ２ ) ｒ NR ａ R ａ , -(CH ２ ) ｒ NR ａ C(=O)R ｂ , -NR ａ C(=O)OR ｂ , -C(=O)OR ｂ , C(═O)NR ａ R ａ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ６ are H and 0 to 4 R ｅ C substituted with １－３ Alkyl, —S(O) ｐ R ｃ , -C(=O)R ｂ , -C(=O)OR ｂ , -(CH ２ ) ｒ -C(=O)NR ａ R ａ , -C(=O)(CH ２ ) ｒ NR ａ C(=O)R ｂ , -S(O) ｐ NR ａ R ａ , 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ａ are H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ or R ａ and R ａ and the nitrogen atom to which both of these are bonded and together form 0 to 5 R ｅ forming a heterocyclic ring substituted with R ｂ are H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ Alkenyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of these has 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｅ Each of these has 0 to 5 R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, F, Cl, Br, CN, NO ２ , =O, -NH ２ , -NHC １－４ Alkyl, —N(C １－４ alkyl) ２ , -C(=O)OH, -C(=O)OC １－４ Alkyl, -(CH ２ ) ｒ OH, and -(CH ２ ) ｒ O.C. １－４ independently selected from alkyl; R ｆ each optionally substituted with H, F, Cl, Br, CN, OH, OH １－５ Alkyl, C ３－６ independently selected from cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3 and 4; 4. The compound of claim 3 or a pharmaceutically acceptable salt thereof.

9. R ４ but, 【Chemistry 24】 selected from: R ５ are H, F, Cl, Br, and C, respectively. １－４ independently selected from alkyl, OH, and —C(═O)OH; 9. The compound of claim 8 or a pharmaceutically acceptable salt thereof.

10. Formula (IV): 【Chemistry 25】 [In the formula: 【Chemical 26】 teeth 【Chemical 27】 Selected from: R ２ is CH ３ and -CH ２ -cyclopropyl; R ３ is H, F, and -OC １－４ alkyl; R ４ teeth, 【Chemical 28】 Selected from: R ５ are H, F, Cl, Br, CN, and C, respectively. １－４ Alkyl, -(CH ２ ) ｒ OR ｂ , -NR ａ S (O) ｐ R ｃ , -NR ａ R ａ , -NR ａ C(=O)R ｂ , -NR ａ C(=O)OR ｂ , -C(=O)OR ｂ , —C(═O)NR ａ R ａ , -NR ａ C(=O)NR ａ R ａ , 0 to 4 R ｅ C substituted with ３－６ cycloalkyl, 0 to 4 R ｅ aryl substituted with, and 0 to 4 R ｅ heterocyclyl substituted with R ６ are H and C, respectively. １－３ independently selected from alkyl; R ａ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｂ are each H and 0 to 5 R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－１０ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｃ Each of the R ｅ C substituted with １－６ alkyl, 0 to 5 R ｅ C substituted with ２－６ alkenyl, 0 to 5 R ｅ C substituted with ２－６ Alkynyl, -(CH ２ ) ｒ -0 to 5 R ｅ C substituted with ３－６ Carbocyclyl, and -(CH ２ ) ｒ -0 to 5 R ｅ heterocyclyl substituted with R ｄ are H and C, respectively. １－３ independently selected from alkyl; R ｅ Each of the R ｆ C substituted with １－６ Alkyl, C ２－６ Alkenyl, C ２－６ Alkynyl, -(CH ２ ) ｒ -C ３－６ Cycloalkyl, -(CH ２ ) ｒ -aryl, F, Cl, Br, CN, NO ２ , =O, -N(C １－４ alkyl) ２ , -C(=O)OH, -(CH ２ ) ｒ OH, and -(CH ２ ) ｒ O.C. １－４ independently selected from alkyl; R ｆ are each optionally substituted with H, F, Cl, Br, CN, OH, or OH; １－５ Alkyl, C ３－６ independently selected from cycloalkyl, and phenyl; each p is independently selected from 0, 1 and 2; and each r is independently selected from 0, 1, 2, 3, and 4; 3. The compound according to claim 2, which is represented by the formula: or a pharmaceutically acceptable salt thereof.

11. R ２ is CH ２ -cyclopropyl; R ３ Ga-OCH ３ and R ４ but 【Chemical 29】 and R ５ are H, F, Cl, Br, and C, respectively. １－４ Alkyl, and -(CH ２ ) ０－１ are independently selected from: OH; and R ｄ is H, 11. The compound of claim 10 or a pharmaceutically acceptable salt thereof.

12. L is —C(═O)NH—; R ２ Ga-CH ２ -cyclopropyl; R ３ Ga-OC １－４ is alkyl; R ４ but, 【Chemistry 30】 Selected from: R ５ are H, F, Cl, Br, and C, respectively. １－４ independently selected from alkyl, —OH, and —CN; 3. The compound of claim 2 or a pharmaceutically acceptable salt thereof.

13. L is —O—; R ２ Ga-CH ２ -cyclopropyl; R ３ Ga-OC １－４ is alkyl; R ４ but, 【Chemical 31】 selected from: R ５ are H, F, Cl, Br, and C, respectively. １－４ independently selected from alkyl, —OH, and —CN; 3. The compound of claim 2 or a pharmaceutically acceptable salt thereof.

14. Formula (VII): 【Chemical 32】 [In the formula: 【Chemical 33】 teeth 【Chemical Formula 34】 Selected from: R ２ Ha-CH ２ -cyclopropyl; R ４ teeth, 【Chemical 35】 Selected from: R ５ are F, Cl, and C, respectively. １－４ Alkyl, -(CH ２ ) ｒ OR ｂ , -S(O) ２ NR ａ R ａ , -NR ａ S (O) ２ R ｃ and —C(═O)NR ａ R ａ more independently selected; R ａ are each H and 0 to 5 R ｅ C substituted with １－４ independently selected from alkyl; R ｂ are each H and 0 to 5 R ｅ C substituted with １－４ independently selected from alkyl; R ｃ each independently represents 0 to 5 R ｅ C substituted with １－４ is alkyl; R ｅ are F, Cl, Br, —OH, and —OC, respectively. １－４ independently selected from alkyl; each r is independently selected from 0, 1 and 2; 3. The compound according to claim 2, which is represented by the formula: or a pharmaceutically acceptable salt thereof.

15. 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((6-fluoropyridin-3-yl)oxy)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylsulfonyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((4-hydroxyphenyl)amino)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indole-6-carboxamide 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxypyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide Methyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxypyridin-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-methyl-1,2-dihydropyridin-2-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(5-methoxypyridin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Methyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]carbamate (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-3-yloxy)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 2-Methoxyethyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]carbamate 2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indol-6-amine 3-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H-pyrazol-1-yl]propanamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrazol-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 2-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]formamide}acetic acid 3-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]formamido}propanoic acid 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N-(pyridin-4-yl)benzamide 2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(pyrimidin-5-yl)-1H-indol-6-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(pyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(5-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1,2-dihydropyridin-2-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrrol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyrimidine-2-carbonitrile 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carbonitrile 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)amino]pyrimidine-2-carbonitrile 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]but-2-ynamide N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]prop-2-enamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,6-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(6-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2-methylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide (1R,4R,7R)-2-{2-[6-(6-aminopyridin-3-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[2-(methylamino)pyrimidin-5-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-fluoro-3-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide (1R,4R,7R)-2-(2-{6-[(3-chloropyridin-4-yl)amino]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine 2-{3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1H-pyrazol-1-yl}ethan-1-ol Methyl 4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-3-carboxylate 4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]benzonitrile (1R,4R,7R)-2-(2-{6-[(3-chloro-2-methylpyridin-4-yl)amino]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(3,5-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,3-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(3-methylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(3-fluoropyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-4-amine N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dimethylpyridin-4-amine N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-amine N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridin-4-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(6-methylpyridin-3-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-2-carbonitrile (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[methyl(pyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine {4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-3-yl}methanol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2-methoxypyrimidin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{[2-(propan-2-yl)pyrimidin-4-yl]amino}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-4,6-diamine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2-methylpyrimidin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyrimidin-4-ol 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-2-carbonitrile N5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2,5-diamine N1-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,4-diamine N1-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,3-diamine 4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]benzamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-(2-{6-[4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenol 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenol [3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanol 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carbonitrile [4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanol Methyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxylate N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethene-1-sulfonamide 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-[2-(dimethylamino)ethyl]benzamide 4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-2-ol 3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]phenol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,5-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)amino]phenol 2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(2,5-dimethylpyridin-4-yl)-1H-indol-6-amine (1R,4R,7R)-2-{2-[6-(3-aminophenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-(2-hydroxyethyl)benzamide {4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-2-yl}methanol [5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]methanol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylbenzamide 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[1-(propan-2-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[1-(2-methylpropyl)-1H-pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylpyridine-2-carboxamide Methyl 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-2-carboxylate 1-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3-methylidenepyrrolidin-2-one N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]-N-methylprop-2-enamide N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]-3-methylbut-2-enamide N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]prop-2-enamide N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-N-methylethene-1-sulfonamide 1-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]-3-methylidenepyrrolidin-2-one N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]-N-methylprop-2-enamide 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[6-(methylsulfanyl)pyridin-3-yl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzoic acid Ethyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-indole-2-carboxylate (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(6-methanesulfonylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 2-Methoxyethyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(1-cyclopropyl-1H-pyrazol-4-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-(2-{6-[4-(aminomethyl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,2,3,4-tetrahydroquinolin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-methylprop-2-enamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyrimidine-2-carboxamide 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyrimidine-2-carboxamide {5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}methanol 6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1,3-benzoxazol-2-one 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1H-isoindol-1-one 6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2-methyl-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one (1R,4R,7R)-2-{2-[6-(1-benzofuran-5-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 1-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethan-1-ol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1-benzofuran-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methyl-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one Cyclopropylmethyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]carbamate (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(ethanesulfonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidine-2,4-dione 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one Methyl 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyrimidine-2-carboxylate 1-{6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1H-indol-1-yl}ethan-1-one Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]carbamate [4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]urea 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylbenzamide 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylbenzamide [2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methoxyphenyl]methanol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol 6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1,2,3,4-tetrahydroquinolin-2-one [2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methoxyphenyl]methanol (1R,4R,7R)-2-{2-[6-(4-amino-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(4-amino-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]carbamate Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]carbamate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-chlorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3,5-difluorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,5-difluorophenol [4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorophenyl]methanol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorophenol [4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenyl]methanol 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,3-dihydro-2-benzofuran-1-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one 2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-1-methyl-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one Methyl N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methyl-1,2-dihydroquinolin-2-one (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxypyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methyl-1,2,3,4-tetrahydroquinazolin-2-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 2-amino-3-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]propanoic acid N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}acetamide N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}methanesulfonamide Methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-oxo-1,2-dihydroquinoline-4-carboxylate 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxy-3-methyl-1,2-dihydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinolin-2-one N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methyl}acetamide N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methyl}methanesulfonamide Methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-oxo-1,2-dihydroquinoline-4-carboxylate 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxy-3-methyl-1,2-dihydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydroquinolin-2-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-2,3-dihydro-1H-indol-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroisoquinolin-1-one 2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetic acid 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzene-1,3-diol 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydroisoquinolin-1-one 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydroquinolin-2-one 2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[6,6'-biindol]-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-methyl-1,2,3,4-tetrahydroquinazolin-2-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-2-one 2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide 2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-N-methylacetamide 2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-N-(2-hydroxyethyl)acetamide 2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-N-(2-methanesulfonylethyl)acetamide 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-(hydroxymethyl)-1,2-dihydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoro-8-methyl-1,2-dihydroquinolin-2-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydropyridin-2-one N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]acetamide N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]acetamide N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methanesulfonamide 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-methyl-1,2-dihydroquinolin-2-one 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-(hydroxymethyl)-1,2-dihydroquinolin-2-one 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]carbamate N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]methanesulfonamide Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-difluorophenyl]carbamate 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenyl]carbamate N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorophenyl]methanesulfonamide Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-difluorophenyl]carbamate 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorophenol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxy-3-methyl-1,2-dihydroquinolin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 2-amino-4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(isoquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl acetate (1R,4R,7R)-2-{2-[6-(3-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-fluoro-4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(3-chloro-4-fluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(3-chloro-4,5-difluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-fluoro-4-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(1,3-benzothiazol-5-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3-thiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(2-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(1,3-benzothiazol-5-yl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3-thiazol-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-4-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(2-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-difluoro-4-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,4,5-trifluorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluoro-3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,4,5-trifluorophenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluorophenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[6-(4-chloro-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluoro-3-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzoic acid 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorobenzoic acid 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorobenzoic acid 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorobenzoic acid 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorobenzoic acid 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one [3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methanol [3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-fluorophenyl]methanol [3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenyl]methanol [5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenyl]methanol N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]acetamide [3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenyl]methanol [3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]methanol [5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]methanol N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-acetamidobenzoic acid 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-acetamidobenzoic acid Methyl N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]carbamate 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenol 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol Methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]carbamate 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-fluorophenol N-{[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methyl}acetamide 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5-fluorophenol 2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-6-fluorophenol N-{[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}acetamide 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-difluoropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-{[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}methanesulfonamide Methyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-indole-2-carboxylate Ethyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-1,3-benzodiazole-2-carboxylate 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-2,3-dihydro-1H-indol-2-one Ethyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H-1,3-benzodiazole-2-carboxylate 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one 2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-7-fluoro-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxy-1,2-dihydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-4-ol Methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-2-carboxylate Methyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-benzothiophene-2-carboxylate 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)naphthalen-2-ol 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxy-1,2-dihydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-4-ol Methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxynaphthalene-2-carboxylate 2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-2',3'-dihydro-1H,1'H-[6,7'-biindol]-2'-one 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1-sulfonamide 2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorobenzamide 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorobenzamide 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzene-1-sulfonamide 2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-6-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide Methyl N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenol Methyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenyl acetate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl acetate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorobenzamide 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-fluorobenzamide 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridine-2-carboxamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methylquinolin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methylquinolin-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxybenzamide 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-1-ium-1-olate 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-3-carboxylic acid 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2,3,4-tetrahydroquinolin-2-one 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-methoxybenzamide 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-1-ium-1-olate 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylic acid 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-8-fluoro-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinoline-2-carbonitrile 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-hydroxybenzamide 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2-carbonitrile 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzamide 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-6-methoxyphenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorophenol 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylbenzene-1-sulfonamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinoxalin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-cyclopropylbenzene-1-sulfonamide Methyl N-[5-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate 4-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide 4-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide 6-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroisoquinolin-1-one 5-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorobenzamide 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinazolin-4-ol 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoxalin-2-ol Methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2-carboxylate 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinoxalin-2-ol 5-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indol-6-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide Methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinoline-2-carboxylate 4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorobenzamide 2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-3,3-difluoro-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cinnolin-4-ol 2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-4-chloro-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one 2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[(pyridin-4-yl)methyl]-1H-indol-6-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-4-yloxy)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,6-dimethylpyridin-4-yl)oxy]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(pyridin-3-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-{5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-2-yl}acetamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridine-4-sulfonyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-[2-(6-{[4-(aminomethyl)phenyl]amino}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine 3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]benzamide (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{[(pyridin-4-yl)methyl]amino}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-(3-{[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]methyl}phenyl)acetamide (1R,4R,7R)-2-[2-(6-{[3-(aminomethyl)phenyl]amino}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-ethoxypyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3-benzotriazol-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3-benzotriazol-6-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1,3-benzoxazol-2-one 2-(4-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy)acetamide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinazolin-4-ol Methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate 6-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-methyl-1H-benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)isoquinolin-2-ium-2-olate 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,3-difluoro-2,3-dihydro-1H-indol-2-one 6-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cinnolin-4-ol 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-2-ium-2-olate S-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-hydroxyethane-1-sulfonamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide 4-[(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2-methoxyphenol 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinazolin-4-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-methoxy-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-hydroxy-1,2,3,4-tetrahydroquinolin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinolin-2-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1-sulfonamide 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one Ethyl 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylate 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-4-ol 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-4-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,8-naphthyridin-2-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,8-naphthyridin-2-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2-carboxamide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-2-carboxylic acid 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-2-carboxylic acid ((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-hydroxyquinolin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-5-yl)methanone 5-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)indolin-2-one 6-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one 5-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-2(1H)-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-5-one Methyl (5-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl)carbamate Methyl (4-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl)carbamate Methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-pyrrole-2-carboxylate Methyl N-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]carbamate 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-hydroxy-3-methyl-2,3-dihydro-1H-indol-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-3-carbonitrile Ethyl 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylate 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carbonitrile 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-1-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-(2-hydroxy-2-methylpropyl)-1,2-dihydroquinolin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)isoquinolin-1-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-(2-hydroxy-2-methylpropyl)-1,2-dihydroquinolin-2-one 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluorobenzamide 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluorobenzamide 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[3,2-b]pyridin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-2,3-dihydro-1H-isoindol-1-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-7-fluoro-2,3-dihydro-1H-isoindol-1-one 1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-phenylethan-1-ol (diastereomeric mixture) 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-3-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazolin-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-1,2,3,4-tetrahydroquinolin-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazolin-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-7-fluoro-1,2,3,4-tetrahydroquinolin-2-one Methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzoate Methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorobenzoate 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-7-methoxy-1,2,3,4-tetrahydroquinolin-2-one 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-6-fluorobenzamide 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5-fluorobenzamide Methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorobenzoate Methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorobenzoate 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorobenzene-1-sulfonamide 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenol 2'-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-6-fluoro-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-difluorobenzene-1-sulfonamide 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorophenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5-fluoro-2-methoxyphenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-(2-hydroxyethyl)benzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylbenzene-1-sulfonamide 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methyl-1,2-dihydroquinolin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-2,3-dihydro-1H-indol-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-2,3-dihydro-1H-indol-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-5-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorobenzene-1-sulfonamide 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-hydroxy-1,2,3,4-tetrahydroquinolin-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzamide 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-4-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinazolin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,8-naphthyridin-2-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-2-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2,4-diol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylquinolin-4-ol 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-1-ol Methyl 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzoate Methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzoate 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylquinolin-4-ol 5-(2-{5-[(3S,4R)-3-amino-4-hydroxypiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-1-ium-1-olate 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-2-ium-2-olate 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinazolin-4-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoxalin-2-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroisoquinolin-1-one Methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methyl-1H-pyrazole-3-carboxylate 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide Methyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzoate Ethyl 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]acetate 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2-dihydroquinolin-2-one 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-methoxy-1,2,3,4-tetrahydroquinolin-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxybenzamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-2,3-dihydro-1H-indol-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione Methyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methyl-1H-pyrazole-3-carboxylate (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carbonitrile N-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-4-amine 6-[(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1H-isoindol-1-one 6-amino-2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-2,3-dihydro-1H-indol-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-(trifluoromethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one 8-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-3-methyl-1,2-dihydroquinoxalin-2-one 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenoxy]-2-methylpropan-2-ol 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-N-(4-carbamoyl-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide (7R)-2-{2-[1-(cyclopropylmethyl)-6-{4-[(pyridin-4-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]ethan-1-ol N-[2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]ethan-1-ol N-[2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamide 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(4-sulfamoylphenyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(4-hydroxy-3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[3-(hydroxymethyl)pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-6-carboxamide 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(3-sulfamoylphenyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(2-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzene-1-sulfonamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorobenzene-1-sulfonamide 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzene-1-sulfonamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorobenzene-1-sulfonamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(1,2-oxazol-5-yl)phenol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methylpyridin-3-ol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(1,2-oxazol-5-yl)phenol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methylpyridin-3-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2,3,4-tetrahydroquinolin-2-one 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]acetamide Methyl 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenoxy]acetate 2-[6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]acetamide 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-2-hydroxyacetamide (diastereomeric mixture) 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]acetamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorobenzamide 2-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]acetamide 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-2-hydroxyacetamide (diastereomeric mixture) 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]acetamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorobenzamide 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(6-methanesulfonylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one 4-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]azetidin-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridine-2-carboxamide [5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1-benzofuran-2-yl]methanol 3-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-4,5-dihydro-1,2,4-oxadiazol-5-one 4-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]azetidin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridine-2-carboxamide [5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1-benzofuran-2-yl]methanol 3-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-4,5-dihydro-1,2,4-oxadiazol-5-one (7R)-2-{2-[1-(cyclopropylmethyl)-6-{4-[(1,3-oxazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Methyl 2-{2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]acetamide}acetate Methyl (2E)-3-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]prop-2-enoate (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{4-[(1,3-oxazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1-benzofuran-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one 2-Methoxyethyl N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1-benzofuran-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 3-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]propanoic acid Ethyl 2-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetate 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-ol [5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]methanol [4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenyl]methanol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1-benzofuran-3-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoropyridin-3-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoropyridin-3-ol 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]pyrrolidin-2-one [4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenyl]methanol [4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenyl]methanol [4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]methanol [4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenyl]methanol [4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]methanol 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]-N-(cyanomethyl)acetamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylpyridine-2-carboxamide 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H-[1,3]oxazolo[4,5-b]pyridin-2-one [2-amino-5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]methanol 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxypyridin-3-ol [4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoropyridin-3-ol [5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridin-2-yl]methanol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H-[1,3]oxazolo[4,5-b]pyridin-2-one [2-amino-5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]methanol 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxypyridin-3-ol [4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoropyridin-3-ol [5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridin-2-yl]methanol 1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methoxypyridin-2-yl]pyrrolidin-2-one 1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-3-hydroxypyrrolidin-2-one (diastereomeric mixture) 1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridin-2-yl]-3-hydroxypyrrolidin-2-one (diastereomeric mixture) 1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3-hydroxypiperidin-2-one (diastereomeric mixture) 1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one 1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one 1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methoxypyridin-2-yl]pyrrolidin-2-one 1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-3-hydroxypyrrolidin-2-one (diastereomeric mixture) 1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridin-2-yl]-3-hydroxypyrrolidin-2-one (diastereomeric mixture) 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3-hydroxypiperidin-2-one (diastereomeric mixture) 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one 2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-hydroxybenzonitrile 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxybenzonitrile 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-hydroxybenzonitrile 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxybenzonitrile 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol 2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzonitrile 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzonitrile 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenol 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylpyridine-2-carboxamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol 1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-3-hydroxypiperidin-2-one (diastereomeric mixture) 4-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2,3-dihydro-1H-imidazol-2-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzonitrile 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzonitrile 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzonitrile 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridin-4-ol 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-3-hydroxypiperidin-2-one (diastereomeric mixture) (7R)-2-{2-[6-(6-amino-5-methoxypyridin-3-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2,3-dihydro-1H-imidazol-2-one ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-(1,1-dioxidoisothiazolidin-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 5-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-5-methylimidazolidine-2,4-dione 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione ((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(1,1-dioxidoisothiazolidin-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 5-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-5-methylimidazolidine-2,4-dione (diastereomeric mixture) 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxy-1,2-dihydropyridin-2-one 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-2-ol (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-ol N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-2,2-dimethylpropanamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]cyclopropanesulfonamide N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2,2-dimethylpropanamide N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-2,2-dimethylpropanamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]cyclopropanesulfonamide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-3-ol (7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-ol 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,5-difluorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N-(2-hydroxyethyl)benzamide N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]acetamide 2'-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[5,6'-biindol]-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-methyl-1,2-dihydropyridin-2-one 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1,2-dihydropyridin-2-one 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,4-dimethyl-1,2-dihydropyridin-2-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,4-dimethyl-1,2-dihydropyridin-2-one 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,3-diol 1-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-3-yl]-3-hydroxypyrrolidin-2-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,3-diol 1-[6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-3-yl]-3-hydroxypyrrolidin-2-one (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-5-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-1-ium-1-olate 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)isoquinolin-2-ium-2-olate 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cinnolin-4-ol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylic acid 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-2-ol 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one 7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-hydroxybenzamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(6-methanesulfonylpyridin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-difluorobenzene-1-sulfonamide 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-8-fluoro-4-hydroxyquinoline-3-carboxylic acid 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydropyridin-2-one N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methanesulfonamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N,N-dimethylpyridine-2-carboxamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N-methylpyridine-2-carboxamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-3-carbonitrile 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carbonitrile (7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(morpholine-4-sulfonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-(hydroxymethyl)benzonitrile N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenyl]methanesulfonamide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-4-hydroxyquinoline-3-carboxylic acid 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-(hydroxymethyl)benzonitrile N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenyl]methanesulfonamide 2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-1,2,3,4-tetrahydroisoquinolin-1-one 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinazoline-2,4-diol 6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one Methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-cyclopropanamidopyridine-4-carboxylate N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chloropyridin-2-yl]acetamide [2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-yl]methanol [6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]methanol (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Methyl 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-cyclopropanamidopyridine-4-carboxylate N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chloropyridin-2-yl]acetamide [3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorophenyl]methanol (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxy-3-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dimethylphenol [3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]urea N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-hydroxypyridin-2-yl]acetamide N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-(hydroxymethyl)pyridin-2-yl]acetamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2-methoxy-3-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dimethylphenol [3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]urea 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H-indazol-5-ol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-chloro-2-methylphenol 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-chloro-2-methylphenol (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 5-(2-{5-[(6S,7R)-7-amino-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethan-1-ol (7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-dimethoxypyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-4-methanesulfonylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one 8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-methoxyacetamide N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-methoxyacetamide 1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-1-yl]ethan-1-one (3R,5R)-1-{2-[6-(1,2,4-benzotriazin-6-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[6-(1,3-benzoxazol-4-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (7R)-2-{2-[6-(1,2,4-benzotriazin-6-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylphenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylphenol 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol (7R)-2-{2-[1-(cyclopropylmethyl)-6-{4H,5H,6H,7H-pyrazolo[1,5-a]pyridin-3-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Ethyl 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-pyrazol-1-yl]acetate 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chlorophenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-chlorophenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chlorophenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chloro-4-fluorophenol (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxybenzonitrile 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-6-methylphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-ethylphenol Ethyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dimethyl-1H-pyrazole-5-carboxylate 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-pyrazol-1-yl]-2-methylpropan-2-ol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-methylphenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(trifluoromethyl)phenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-methylphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(trifluoromethyl)phenol 3-{[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamide}propanamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-[(1-carbamoylcyclopropyl)methyl]benzamide (7R)-2-{2-[1-(cyclopropylmethyl)-6-(5-methoxy-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Ethyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,5-dimethyl-1H-pyrazole-3-carboxylate Methyl 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-indazole-6-carboxylate (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-{pyrazolo[1,5-a]pyridin-3-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[6-(3-cyclopropyl-1H-pyrazol-4-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxy-6-methylphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenol 3-{[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamide}-2,2-dimethylpropanamide [4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-fluorophenyl]methanol 3-{[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamide}-2,2-dimethylpropanamide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7aH-pyrrolo[3,2-b]pyridine-3-carboxamide 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-(trifluoromethyl)phenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-dimethylphenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methylphenol 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorophenol 1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxyphenyl]acetamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one [4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]methanol 1-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one 1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]acetamide 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenyl]acetamide 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorophenyl]acetamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one [4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]methanol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-dimethylphenol [4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]methanol (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[4,3-a]pyridin-3-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Ethyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,5-dimethyl-1H-pyrazole-3-carboxylate (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine Ethyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dimethyl-1H-pyrazole-5-carboxylate Methyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-pyrazole-5-carboxylate (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-dimethylphenol 2-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide (2E)-3-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]prop-2-enamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methylpyridine-2-carboxamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxypyridine-2-carboxamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridine-2-carboxamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-dimethylphenol 2-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide (2E)-3-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]prop-2-enamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methylpyridine-2-carboxamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxypyridine-2-carboxamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridine-2-carboxamide (2E)-3-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]prop-2-enamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-ol (diastereomeric mixture) 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-ol (diastereomeric mixture) (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3-triazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]propan-1-ol (diastereomeric mixture) 1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethan-1-ol (diastereomeric mixture) (7R)-2-{2-[1-(cyclopropylmethyl)-6-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-[5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxybenzamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxybenzamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridine-2-carbonitrile 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carboxamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carboxamide [5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidin-2-yl]methanol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-6-methoxyphenol 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridine-2-carbonitrile 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dimethylphenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-difluorophenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-dichloro-3-methylphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dimethylphenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-difluorophenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-dichloro-3-methylphenol 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxy-2-methylbenzoic acid 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(hydroxymethyl)phenol 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorobenzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-3-methylbenzamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(hydroxymethyl)phenol 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorobenzamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-3-methylbenzamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-1-ol (diastereomeric mixture) 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-fluorobenzamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-fluorobenzamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)phenyl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]acetamide N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylphenyl]acetamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[2-fluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)-2-methylphenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-(2-{6-[2-chloro-4-(methanesulfonylmethyl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-5-fluoropiperidin-3-amine N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-yl]acetamide (diastereomeric mixture) 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxy-2-methylbenzamide N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]acetamide N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylphenyl]acetamide (7R)-2-{2-[1-(cyclopropylmethyl)-6-[2-fluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-(2-{6-[2-chloro-4-(methanesulfonylmethyl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)-2-methylphenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-yl]acetamide (diastereomeric mixture) 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxy-2-methylbenzamide 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorobenzamide N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridin-2-yl]acetamide (2E)-N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]-3-ethoxyprop-2-enamide 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridin-2-yl]acetamide 1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethane-1,2-diol (diastereomeric mixture) 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzamide (7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-fluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylbenzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylbenzamide 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylbenzamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylbenzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[2,5-difluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine Methyl N-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]carbamate Methyl N-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]carbamate 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(trifluoromethyl)benzamide 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzoic acid (7R)-2-{2-[1-(cyclopropylmethyl)-6-[2,5-difluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)-3-methylphenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine Methyl N-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]carbamate Methyl N-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]carbamate 2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluorobenzoic acid (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(5-methanesulfonylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine 2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluorobenzoic acid (7R)-2-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-ethylpyridin-2-yl]acetamide 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridine-2-carboxamide 2-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide Methyl N-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]carbamate 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methylbenzamide N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-ethylpyridin-2-yl]acetamide 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridine-2-carboxamide 2-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide Methyl N-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]carbamate 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methylbenzamide Methyl 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-pyrazole-3-carboxylate 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-3-carboxamide [3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chloropyridine-3-carboxamide Methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-pyrazole-3-carboxylate (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{3-fluoro-2-methylpyrazolo[1,5-a]pyridin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2-methylpyrazolo[1,5-a]pyrimidin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine (7R)-2-{2-[1-(cyclopropylmethyl)-6-{3-fluoro-2-methylpyrazolo[1,5-a]pyridin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine 1-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3,3-dimethylurea, or (7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(difluoromethyl)-2-fluorophenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine or a pharmaceutically acceptable salt thereof.

16. A pharmaceutically acceptable composition comprising a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or excipient.

17. 17. The composition of claim 16 in combination with an additional therapeutic agent.

18. A composition comprising a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for inhibiting PAD4.

19. 16. A pharmaceutical composition comprising the compound of any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for treating a PAD4-mediated disease, disorder, or condition selected from the group consisting of acute lymphocytic leukemia, ankylosing spondylitis, cancer, chronic lymphocytic leukemia, colitis, lupus, rheumatoid arthritis, multiple sclerosis, and ulcerative colitis.

20. 20. The pharmaceutical composition of claim 19, wherein the PAD4-mediated disease, disorder, or condition is selected from rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, ulcerative colitis, and cancer.

21. A compound according to any one of claims 1 to 15 or a composition according to claim 16 for use in therapy.

Images